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Abstract  
 
 
Chronic Kidney Disease (CKD) is a major global health burden. In the United States alone, 
roughly 30 million Americans have CKD. Each year in the United States, thousands of CKD 
patients progress toward the most severe form of CKD, End-Stage Renal Disease (ESRD). Once 
patients reach ESRD, costly renal replacement therapy is needed to sustain life.  Striking disparities 
also exist within the CKD patient population. In fact, Native Americans, Americans of African 
descent, Native Hawaiians, and Asians are several times more likely to advance to ESRD relative 
to Americans of European descent. To decrease the burden of CKD, effective early interventions 
and accessible therapeutics are desperately needed.  
Bone Morphogenetic Protein (BMP) signaling is critical in renal development and disease. 
In animal models of CKD or kidney fibrosis, re-activation of BMP signaling is reported to be 
protective by promoting renal repair and regeneration. Clinical use of recombinant BMPs, 
however, requires high and harmful doses to achieve efficacy. BMPs are also expensive 
therapeutic agents to use clinically due to the complexity of their synthesis. Consequently, 
alternative strategies are needed to harness the beneficial properties of BMP signaling in fibrotic 
kidneys. The first aim of the work in this dissertation was to identify simpler to synthesize small-
molecules that could potentially be developed further to treat kidney disease. Therefore, current 
and powerful high-throughput screening (HTS) methodologies used for drug discovery were 
implemented to assess approximately 64,000 small-molecules in human kidney cells. These cells 
have a genomically integrated BRE-Luc reporter making them highly responsive to BMPs. The 
 xi 
HTS campaign identified twelve small-molecules that activated the BRE-Luc reporter in a dose-
dependent manner. Of these compounds, sb4, displayed the lowest EC50 (74 nM) and further 
investigations revealed its capacity to induce key downstream BMP signaling events. For instance, 
in the presence of sb4 levels of key second messengers in BMP signaling, p-SMADs-1/5/9, rapidly 
increased. Additional studies suggested that the increase in p-SMADs-1/5/9 was likely due to 
stabilization by sb4, which resulted in activation of BMP target genes, ID1 and ID3. These results 
are significant as they demonstrate the feasibility of identifying small-molecules using HTS that 
mimic key downstream BMP signaling events. Accordingly, compounds like sb4 could prove 
useful in clinically treating fibrosis by activating the BMP signaling pathway. Furthermore, sb4 
also resists inhibition by endogenous BMP inhibitors, such as Noggin. This mechanistic feature 
may prove advantageous in clinical settings where BMPs alone are ineffective due to elevated 
levels of Noggin, which suppress BMP signaling.  
Proliferative kidney diseases such as cystic kidney disease and kidney cancer are subtypes 
of CKD. Pax2, a critical transcription factor required for kidney development is generally 
undetectable in mature nephrons. However, Pax2 is reactivated in proliferative kidney diseases 
and correlates with disease progression. Inhibiting Pax2 arrests cystogenesis and decelerates 
kidney cancer, which makes Pax2 a potential therapeutic target. Thus, the second aim of this 
dissertation was to identify small-molecule inhibitors of Pax2. Re-mining efforts lead to the 
discovery of an emerging lead series of promising Pax2 inhibitors. These Pax2 inhibitors can 
potentially be further developed into therapeutics that could reverse kidney disease or manage it 
with less side effects than current FDA-approved agents. Ultimately, the BMP signaling agonists 
and Pax2 inhibitors identified can be further enhanced and used as tools to advance biomedical 
knowledge of pathophysiological processes of various forms of CKD.   
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 - Introduction to Chronic Kidney Disease and its evolving therapeutic landscape 
 
Abstract  
 
Chronic Kidney Disease (CKD) is deemed a silent killer as it typically progresses over 
long periods of time without noticeable symptoms. Ultimately, CKD advances toward End-Stage 
Renal Disease (ESRD) and can be deadly if left untreated.  Diabetes and hypertension are the 
leading risk factors for developing ESRD. As such, to slow the progression of kidney disease it is 
necessary to strictly control diabetes and hypertension. However, even with carefully managed 
diabetes and hypertension patients can still progress toward ESRD. Presumably, this is because 
the underlying drivers of kidney disease progression are not directly targeted by these treatments. 
Once patients reach ESRD, renal replacement therapy is required to sustain life. Two clinical 
options for managing ESRD exist and include chronic dialysis treatment or kidney transplantation.  
Though these clinical options help sustain life, they are costly and burdensome to the patients 
receiving these treatments. Consequently, many patients succumb to disease while undergoing 
dialysis or while waiting for a kidney transplant.  
Therefore, alternative therapeutics are needed to manage and potentially reverse chronic 
kidney disease. TGF-b and BMP signaling are both implicated in CKD. Longstanding studies have 
demonstrated that TGF-b contributes to driving the progression of CKD. Whereas, BMP signaling 
has been reported by numerous studies to reverse CKD. Various drug development programs for 
the treatment of CKD have been heavily centered and designed around targeting pathological 
levels of TGF-b. However, futile results were recently reported for clinical trials aimed at 
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suppressing pathological levels of TGF-b1 with monoclonal antibodies. Another strategy to 
modulate TGF-b signaling is to activate BMP signaling, which counters the disease-causing effects 
of TGF-b. Chapter 1 provides an overview of the various strategies that have been employed to 
develop novel agents that target the TGF-b system for the treatment of CKD. Additionally, studies 
that have provided evidence of renoprotection by BMPs in the pathological context of 
CKD/fibrosis are also reviewed.  
Lastly, Chapter 1 provides an overview of proliferative diseases of the kidney such as 
polycystic kidney disease and clear cell renal cell carcinoma.  Current treatment strategies for these 
proliferative renal diseases and potential targets for therapeutic intervention are also discussed. 
.  
 3 
Overview of Chronic Kidney Disease epidemiology and pathophysiology   
 
Chronic Kidney Disease (CKD) develops as an injurious and gradual loss of kidney 
function over several decades of life without noticeable symptoms. Patients with CKD can 
progress to having 10% of kidney function or End-Stage Renal Disease (ESRD) before 
experiencing any symptoms. Globally, some 720 million people have CKD [1]. Equally 
concerning, the prevalence of ESRD, the most severe type of CKD, is steadily rising; especially, 
in the United States where ESRD has risen 86% since 2000 [2]. Nearly 30 million Americans are 
afflicted with CKD and at least 100,000 of these patients progress towards ESRD each year [2]. 
There are currently over 700,000 prevalent cases of ESRD in the United States [2].  
Marked disease disparities complicate the burden of CKD in the United States. Native 
Americans, Americans of African descent, Native Hawaiians, and Asians are several times more 
likely to reach ESRD relative to Americans of European descent [2]. Causes that contribute to 
CKD disparities included behavioral, socioeconomical, and environmental determinants. Genetic 
factors such as variants in the apolipoprotein L1 (APOL1) gene have also emerged to account for 
the excess risk in CKD disparity among Americans of African descent [3].  Similar to sickle cell 
anemia genes that are protective from malaria, APOL1 risk alleles are protective from African 
sleeping sickness, which although rare is endemic in parts of sub-Saharan Africa [4].   However, 
and alarmingly, patients with two APOL1 risk alleles are 3-100 times more likely to develop CKD 
compared to those lacking the risk alleles [5, 6].   
Diabetes, hypertension, glomerulonephritis, and cystic kidney disease are the leading risk 
factors for developing ESRD [2]. Another risk factor for developing ESRD is kidney cancer 
specifically, the clear-cell renal cell carcinoma (ccRCC) subtype [7]. Of note, the risk for 
developing kidney cancer or kidney failure functions bidirectionally, with CKD patients being at 
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an increased risk for developing ccRCC and vice versa [7]. For example, type II diabetes induced 
CKD also puts patients at risk for developing kidney cancer [7, 8]. More risk factors for developing 
ESRD include chronic use of NSAIDs and a family history of CKD. As the causes of CKD are 
varied and complex, long-term management is economically burdensome. In 2016, nearly $114 
billion of the Medicare budget or 23% was allocated to kidney disease patients, with over $79 
billion spent on CKD treatment and $35 billion spent on ESRD treatment [9].  
As outlined above, the etiology of CKD can vary. Regardless of the underlying cause, CKD 
ultimately progresses to total kidney failure. No cures or targeted molecular therapies for CKD are 
available. The current therapeutic options for ESRD are limited to either chronic dialysis treatment 
or kidney transplantation. Chronic dialysis treatment is costly with per capita treatment per year at 
$90,971 for hemodialysis and $76,177 for peritoneal dialysis [9]. Strikingly, chronic dialysis 
treatment only restores roughly 15% of kidney function. This is reflected by the shortened patient 
life expectancy after starting dialysis treatment. In 2016, a patient on chronic dialysis between the 
ages of 50-54 years old could expect to live approximately 8 years after starting treatment [10]. 
With a kidney transplantation, which costs $34,780,  the same 50-54 year old patient could expect 
to live at least 20 years [9, 10]. At least 90,000 candidates are currently on the waitlist for a kidney 
transplantation and wait times vary widely between less than 30 days to more than 5 years [11]. 
Regrettably, many patients succumb to disease while waiting for a kidney donation. Neither 
chronic dialysis treatment nor kidney transplantation are a cure for ESRD. As such, individuals 
50-54 years old in the general United States population still have a greater life expectancy (27-31 
years) compared to dialysis or transplant patients [10]. 
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Fibrosis is the principal histopathological finding in patients with CKD.  At the molecular 
level, fibrogenesis is primarily driven by the cytokine TGF-b. Under normal physiological 
conditions, TGF-b is transiently released in response to injury in order to initiate and later 
terminate the process of tissue repair [12]. However, under pathophysiological conditions or 
sustained injury, TGF-b release persists and feeds into an injurious cycle of excessive extracellular 
matrix (ECM) tissue deposition. Excessive ECM deposition damages complex functional 
compartments of the kidney such as the vasculature, glomerulus, and tubulointerstitium [13].  
Along with its normal physiological role of shaping tissue structure to support tissue 
function, the ECM is also important for tissue repair and regeneration [14]. Therefore, in tissues 
with disturbed ECM homeostasis compromised by overactive TGF-b, tissue loss can ensue 
(excessive ECM degradation) or tissue fibrosis and scarring can occur (excessive ECM 
accumulation) [14]. Fibrotic kidneys, therefore, at the histological level exhibit an excessive 
deposition of TGF-b induced extracellular matrix particles, which primarily consists of fibrous 
proteins such as collagens and hydrogel forming proteoglycans such as perlecan [15]. These 
particles can cause the glomerulus (capillaries) to become sclerotic and/or, the kidney interstitial 
space which typically consists of physiological levels of extracellular matrix, fluid, and multiple 
cellular constituents such as fibroblasts can become fibrotic [16, 17]. Continued damage of these 
functional structures by ECM overtime leads to the development of CKD which later culminates 
as ESRD.  
While TGF-b drives fibrogenesis at the molecular level [18, 19], at the cellular level, 
myofibroblasts promote the fibrogenic scarring process.  Under normal physiological conditions 
interstitial fibroblasts are quiescent and few in number. However, overactive TGF-b stimulates the 
abnormal proliferation and accumulation of interstitial fibroblasts. These activated fibroblasts, 
 6 
termed myofibroblast, secrete excessive levels of ECM such as collagens and a-smooth muscle 
actin and thereby, at the cellular level drive fibrogenesis  [13, 20-22].  
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Current therapeutic landscape for Chronic Kidney Disease management  
 
As previously mentioned, no cures or targeted molecular therapies for CKD exist. 
However, since diabetes and hypertension are the leading primary causes of CKD, strict control of 
these ailments help slow CKD to ESRD progression [23-26]. Therefore, modulation of kidney 
hemodynamics is the standard of care for slowing the progression of CKD in patients. This is 
achieved by targeting the Renin-Angiotensin-Aldosterone system (RAAS) with renin enzyme 
inhibitors, angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers 
(ARBs), or mineralocorticoid antagonists to target aldosterone [5].  
Renin enzyme inhibitors such as Aliskiren inhibit the first step of the RAAS cascade, while 
ACEi and ARBs work further downstream. ACEi, such as captopril, block the conversion of 
angiotensin I to angiotensin II. Angiotensin II is induced upon sensing low blood pressure and 
when released acts directly on smooth muscle cells to induce vasoconstriction, which increases 
intraglomerular filtration pressure [5, 27]. Inhibiting the process of converting angiotensin I into 
angiotensin II results in vasodilation and reduced hyperfiltration and proteinuria, which slows the 
progression of CKD to ESRD. ARBs work by competing for the type I angiotensin II receptor.  
Still, patients with controlled diabetes and/or hypertension and modulated kidney 
hemodynamics remain at risk for developing ESRD. These strategies do not stop the progression 
of CKD to ESRD.  In these treatment scenarios, it is likely that the underlying cause for CKD is 
not addressed and damage is still ongoing. Ultimately, novel medications that promote renal repair 
and regeneration are urgently needed and must be practical to synthesize and cost-effective for 
patient accessibility.  
  
 8 
Evolving landscape of therapeutics to treat Chronic Kidney Disease 
 
A breadth of aberrant aspects and molecular targets of CKD have been identified which 
has allowed research, evaluation, and development of novel clinical therapeutics. The evolving 
therapeutic landscape for CKD is largely tailored around diabetes and hypertension treatment. For 
example, in the clinical case of diabetic nephropathy one strategy to slow disease progression 
includes mitigating high levels of systemic glucose via inhibition of the sodium-glucose co-
transporter 2 (SGLT2). The SGLT2 is chiefly responsible for roughly 90% of glucose reabsorption 
in the kidney whereas SGLT1 is responsible for 10% [28]. Due to these transporters, nearly all 
glucose is reabsorbed in the kidneys and therefore virtually untraceable in excreted urine. 
However, in diabetic patients, pathological amounts of glucose in urine are characteristic of this 
disease. High glucose levels overburden the transporters and cause excretion of glucose into the 
urine. SGLT2 inhibitors therefore further promote the process of glucose excretion in the urine 
and are used as a method to lower high blood glucose levels.  Additional effects of SGLT2 
inhibition involves regulating kidney hemodynamics specifically, at the level of the afferent 
arterioles [5]. These agents may also have beneficial effects similar to ACEi and ARB in that they 
lower glomerular filtration pressure and thus stabilize CKD [5]. 
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Targeting the TGF-b system and its pathological effects for the treatment of CKD 
The evolving landscape of novel therapies to treat organ damage caused by fibrosis has 
also been strategically designed around and intensely focused on modulating aberrant transforming 
growth factor-b (TGF-b) activity. TGF-b proteins are multifunctional signaling cytokines with 
essential roles in organ development, homeostasis, and disease. TGF-bs are extremely potent and 
their activity is heavily safeguarded within a large latency complex which consists of latency-
associated proteins (LAPs) and latent-TGF-b-binding proteins (LTBP) [29].  The large latency 
complex sequesters and quarantines TGF-b to the ECM to diffuse its activity (figure 1.1). A 
variety of molecules, on the other hand, are responsible for liberating TGF-b from the large latency 
complex such as, integrin-ab receptors. LAPs of the large latency complex are a substrate for 
integrin-ab receptors and upon binding a conformational change in LAPs invokes liberation of 
bound TGF-b from LAP sequestration.    
Liberation of TGF-b can be triggered by a plethora of stimuli that disturb ECM homeostasis 
including inflammation and would repair [29]. Upon release from the extracellular matrix 
dimerized TGF-b proteins bind to a heterotetramer comprised of type I and type II TGF-b receptors 
(figure 1.1). The constitutively active type II TGF-b receptors phosphorylate the glycine-serine 
domain of the type I TGF-b receptors. In turn, the TGF-b receptors phosphorylate and activate 
receptor activated SMADs (R-SMADs) (figure 1.1). Specifically, TGF-b signaling is transduced 
through R-SMAD-2 and R-SMAD-3 effectors, which form a heteromeric complex with common-
SMAD4 (co-SMAD4) (figure 1.1).  This heteromeric complex drives the expression of target 
genes such as a-smooth muscle actin and collagens which are particularly important molecules in 
fibrogenesis. 
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Figure 1.1 Schematic of the canonical and non-canonical TGF-b signaling pathways. 
Many drug discovery programs have been designed around inhibiting components of both the 
canonical and non-canonical TGF-b signaling pathways. In the TGF-b signaling pathway a large 
latency complex sequesters and quarantines TGF-b to the ECM.  Integrin-ab receptors help 
liberate TGF-bs from the ECM. Upon release from the ECM, dimerized TGF-b ligands bind to a 
heterotetramer comprised of type I and type II TGF-b receptors. The constitutively active type II 
TGF-b receptors phosphorylate the glycine-serine domain of the type I TGF-b receptors. In turn, 
the type I TGF-b receptors phosphorylate and active the TGF-b effectors SMAD-2 and SMAD-3. 
SMADs-2/3 then form a heteromeric complex with co-SMAD4. This heteromeric complex then 
translocates to the nucleus where it drives the expression of target genes such as a-smooth muscle 
actin and collagens which are important in fibrogenesis. Binding of TGF-b ligands to TGF-
b receptors also activates non-canonical TGF-b signaling pathways such as ERK. This figure 
appears in—Sureshbabu, A., S. A. Muhsin and M. E. Choi (2016). "TGF-beta signaling in the 
kidney: profibrotic and protective effects." Am J Physiol Renal Physiol. PMID: 26739888 [30]. 
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The role of TGF-b in inflammation, ECM homeostasis, and its proliferative and anti-
proliferative actions on different cell types has been extensively studied. For instance, 
experimental animal models with ablated TGF-b1 have uncontrolled inflammation and die within 
2-3 weeks [31]. These TGF-b1 heterozygous animals generated by Shull and colleagues exhibit 
significant lesions in the heart and stomach due to infiltration of inflammatory cells such as 
lymphocytes and neutrophils; and, tissues such as the liver and lung are riddled with pro-
inflammatory cytokines (interferon-g, MIP-1a, and TNF-a) [31]. Similarly, TGF-b1 null animals 
generated by Kulkarni and colleagues exhibit inflammatory lesions in the heart and lungs and die 
3-4 weeks after birth due to cardiopulmonary disease [32]. Furthermore, integrin-b6-/- animals, 
which lack the ability to convert latent TGF-b to maturity, also develop uncontrolled 
inflammation.  However, fibrogenesis is suppressed in these animals after bleomycin induced 
pulmonary fibrosis [33]. Additional lines of experimental evidence also confirm that TGF-b  
functions across several organs as a driver of fibrogenesis [34]. These organs include: the kidneys, 
lungs, heart, liver, skin, intestine, and bone marrow [35-40]. 
 
Pirfenidone suppresses the TGF-b system through unknown mechanisms 
Concerted efforts by academic laboratories and pharmaceutical companies have fostered 
the development of a catalog of small-molecules and biologics aimed at inhibiting the TGF-b 
system at multiple levels (table 1.1 and table 1.2). Pirfenidone (Esbrietâ), is an FDA approved 
synthetic small-molecule for the treatment of mild-to-moderate Idiopathic Pulmonary Fibrosis 
(IPF). It has been speculated that Pirfenidone may exert its anti-fibrotic effects though TGF-b 
promoter inhibition, which may result in arrested TGF-b protein synthesis and secretion [41, 42].  
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However, the complete mechanism of action of Pirfenidone is not completely understood. 
Generally, Pirfenidone acts to preserve and protect lung function from the damaging actions of 
overactive TGF-b such as its excessive stimulation of procollagens I and III. However, even under 
Pirfenidone therapy IPF may persist as it only slows disease progression. Animal models of and 
patients with kidney disease have also been treated with Pirfenidone and demonstrated better 
kidney function as assessed by improved estimated glomerular filtration rate (eGFR) [43, 44]. F-
351 is a Pirfenidone analog (10 times more potent) currently being evaluated for safety and 
efficacy for the treatment of chronic viral hepatitis B induced liver fibrosis in a Phase II clinical 
trial sponsored by Shanghai Genomics, Incorporated [45].  
 
BG00011 (STX-100) and VPI-2690B inhibit integrin-ab receptors 
Neutralization of integrin-ab receptors is another strategy to target overactive TGF-b 
activity. In particular, BG00011 (STX-100) is a humanized monoclonal antibody in the Biogen 
Inc. pipeline that selectively targets and deactivates integrin-avb6 receptors [46]. BG00011 has 
been tested in Phase IIa dosage studies and is currently under investigation in Phase IIb efficacy 
studies in patients with IPF (estimated completion date 2021) [47, 48]. Vascular Pharmaceuticals, 
Incorporated have also developed VPI-2690B, a monoclonal antibody that selectively inhibits 
integrin-avb3 receptors. Phase II clinical studies testing the efficacy of VPI-2690B in patients with 
type I and II diabetic kidney disease were completed in March 2017 [49]. 
 
 
 
 
 13 
TGF-b1 is selectively targeted with LY2382770  
Pathological levels of TGF-bs can also be targeted with neutralizing antibodies. Based on 
data from pre-clinical studies in animals with kidney disease, Eli Lilly and Company developed 
LY2382770 (humanized monoclonal antibody) which selectively targets TGF-b1. However, in 
Phase II dosing studies using patients with type I and type II diabetes receiving RAS inhibition 
therapy, efficacy measures (changes in serum creatinine and eGFR ) were not reached and the 
studies were terminated 4 months early (initial 12 month study design) [50]. Voelker and 
colleagues proposed several reasons for lack of efficacy and posited that treating diabetic 
nephropathy patients with anti-TGF-b1 at a less severe stage and/or more frequent administration 
may provide additional strategies to fully inhibit TGF-b1 [50]. Although, effects from prolonged 
and/or over-suppression of TGF-b1 could lead to harmful side effects such as systemic 
inflammatory lesions  [31, 32].  
 
Fresolimumab neutralizes TGF-b1, b2, and b3 ligands 
In addition to selective antibodies that neutralize TGF-b1, pan-anti-TGF-b antibodies have 
also been developed and evaluated in fibrotic diseases. Specifically, Fresolimumab, a humanized 
monoclonal antibody in the Sanofi portfolio, neutralizes all three isoforms of TGF-b (TGF-b1, b2, 
and b3). Fresolimumab has been evaluated in Phase I and Phase II clinical trials in patients with 
steroid-resistant primary focal segmental glomerulosclerosis (SR-FSGS) where TGF-b is reported 
to be increased in patient biopsies [51]. In both Phase I and II studies, tested doses of Fresolimumab 
were determined to be safe and tolerable; however, primary and secondary efficacy measures of 
decreased proteinuria and eGFR respectively were not reached [52, 53].  Interestingly, a small 
subset of FSGS patients (Americans of African descent) showed a significant reduction in 
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proteinuria after just one-single infusion of Fresolimumab in Phase I clinical trials [52]. In Phase 
II clinical trials a similar beneficial effect in Americans of African descent was also observed [53]. 
 
GW788388 inhibits both type I and type II TGF-b kinase receptors 
Pre-clinical investigations in animal models of renal fibrosis have also explored the utility 
of targeting TGF-b receptors to ameliorate the pro-fibrotic effects of TGF-b. In particular, 
GW788388 inhibits both type I and type II TGF-b kinase receptors which results in suppression 
of key pathological events observed in both in vitro and in vivo experimental conditions [54]. 
Semi-quantitative RT-PCR reaction analysis revealed attenuated TGF-b signaling as assessed by 
a reduction in TGF-b target genes (SNAIL, E-cadherin, fibronectin) after GW788388 treatment in 
cells stimulated for 48hr with 5 ngml-1 TGF-b3 [54]. While, a significant reduction in collagen, as 
assessed by immunohistochemical staining, was observed in six-month-old mouse models of 
advanced diabetes-induced renal fibrosis receiving daily oral treatments of GW788388 at 2 mg-
1kg1 for five weeks [54]. Additionally, TGF-b target genes that drive the deposition of excessive 
extracellular matrix such as PAI-1, collagen a1(I), and collagen a1(III) were also significantly 
suppressed in these GW788388 treated type II diabetic animals [54].  
 
IN-1130 and SB-525334 inhibit type I TGF-b kinase receptors 
In a rat model of renal fibrosis, unilateral ureteral obstruction (UUO), the type I TGF-
b receptor inhibitor, IN-1130, was evaluated and demonstrated anti-fibrotic properties. 
Particularly, IN-1130 (intraperitoneally injected at 10 or 20 mg/kg/day for 7 or 14 days, which 
constituted early and late states of fibrogenesis) reduced striking pathological manifestations such 
as tubular loss, atrophy, and dilation; while, these diseased morphological changes persisted in 
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vehicle treated animals [55]. Further, the phosphorylation of TGF-b effector SMAD-2 in rat UUO 
kidneys was significantly downregulated in a dose-dependent manner after 14 days of IN-1130 
treatment compared to UUO vehicle treated groups [55]. Although p-SMAD-2 levels didn’t return 
to basal levels seen in sham operated animals at the doses tested and time points examined (10 and 
20 mg/kg for 14 days) [55].  Similarly, at 14 days or later stages of fibrogenesis, IN-1130 was not 
as efficacious at reducing a-smooth muscle actin (a-SMA) when compared to earlier stages of 
disease [55].  This highlights the possibility that progressive fibrogenesis may be driven by both 
dependent and independent TGF-b pathways [55]. If such is the case, full recovery from fibrotic 
lesions may only be achieved through a combination of therapeutic agents and carefully designed 
treatment regimens.  
Full suppression of fibrotic events was also not achieved with oral administration of the 
type I TGF-b receptor inhibitor, SB-525334.  In puromycin induced renal fibrosis in rats, SB-
525334, significantly suppressed proteinuria relative to untreated animals at 10 mg/kg/day [56]. 
However, proteinuria in these animals still remained at concerning levels of approximately 50% 
of the untreated puromycin induced fibrotic animals (still a sign of damaged kidneys) [56]. 
Likewise, PAI-1 mRNA levels were significantly increased 7.5-fold above control animals and 
although each dose tested (1, 3, 10 mg/kg) significantly reduced PAI-1, levels hovered around 3-
4-fold higher than control levels in control animals, which again suggests additional pathways at 
play in driving fibrogenesis [56]. Procollagen a1(I), and Procollagen a1(III) mRNA expression in 
puromycin induced fibrotic animals was significantly decreased relative to untreated animals with 
significance reached at the 10 mg/kg/day dose [56]. Procollagen a1(I) mRNA levels persisted at 
nearly 1-fold above control animals and Procollagen a1(III) expression leveling near control 
baseline. Interestingly, TGF-b mRNA was not regulated by SB-525334 in the puromycin model 
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of fibrosis whereas, IN-1130 caused a dose-dependent decrease in TGF-b ligand mRNA in UUO 
induced fibrosis [55, 56].  
 
SIS-3 inhibits the TGF-b effector SMAD-3 
TGF-b signaling effectors SMAD-2 and SMAD-3 can also be targeted to modulate 
overactive TGF-b.  SMAD-3 in particular is reported to execute the majority of fibrotic effects 
instigated by TGF-b. Several experimental animal models illustrate ablation of SMAD-3 as a 
potential mechanism to achieve protection from fibrotic lesions. For example, conditional SMAD-
3 knock-out animals are protected from UUO and STZ induced tubulointerstitial fibrosis [57-59]. 
Additionally, reduced collagen IV and fibronectin expression in the tubulointerstitium and 
glomeruli of STZ-induced diabetic mice was observed after treatment with a specific inhibitor of 
SMAD-3 (SIS-3) [60]. Furthermore, confocal microscopy analysis revealed a decrease in the total 
number of a-SMA+ cells in the renal interstitium after SIS-3 treatment in STZ-induced diabetic 
mice [60]. And, although SIS-3 was unable to reduce proteinuria in these animals, levels of serum 
creatine were significantly reduced in SIS-3 treated STZ-induced diabetic mice [60].  
 
Pentoxifylline diminishes TGF-b/SMAD-3/4 signaling 
Pre-clinical and clinical studies evaluating the nonselective phosphodiesterase inhibitor, 
Pentoxifylline (PTX), have also demonstrated encouraging results on mitigating the pro-fibrotic 
effects caused by overactive TGF-b. Specifically, by targeting TGF-b/SMAD-3/4 signaling, PTX 
diminished connective tissue growth factor (CTGF) promoter activity and subsequently collagen 
I (a1) expression induced by CTGF in rat kidney fibroblasts [61]. Additionally, PTX reduced a-
SMA expression induced by CTGF in rat kidney proximal tubular epithelial cells [61]. These 
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CTGF events are regulated upstream by TGF-b/SMAD-3/4 signaling. Furthermore, interstitial 
fibroblasts stimulated with 1 µM of angiotensin II for 4 hours increased both TGF-b1 and CTGF 
gene expression [62]. However, PTX diminished CTGF gene levels but not TGF-b1 gene levels, 
which demonstrated the selective inhibition of PTX towards CTGF [62]. Moreover, rat kidney 
interstitial fibroblasts stimulated with 5 ng/ml of TGF-b1 and treated with PTX at increasing 
concentrations showed a dose-dependent reduction of CTGF at each concentration tested (0, 0.1, 
0.3, 1 millimolar) [62]. Notably, PTX was also able to slow the proliferation of rat interstitial 
fibroblasts in a dose-dependent manner during a 48hr time course experiment [62].        
 In vivo evaluation of PTX in two different models of kidney disease, 5/6 subtotal 
nephrectomy (5/6 Nx) and unilateral ureteral obstruction (UUO), demonstrated beneficial effects 
in lessening disease severity and slowing disease progression [61, 62].  Alongside 
glomerulosclerosis and interstitial fibrotic and inflammatory lesions, 5/6 Nx rats develop 
proteinuria and increased plasma creatinine levels [62].  In each of the aforementioned markers of 
disease progression assessed, PTX significantly decreased each by 40-60% [62]. Furthermore, 
compared to sham operated rats, 5/6 Nx rats develop significant levels of hypertension that PTX 
was unable to positively regulate [62]. Notably, when PTX was combined with Cilazapril (an 
ACEi), not only was uncontrollable hypertension in 5/6 Nx resolved, levels of proteinuria were 
reduced to levels matching those of sham operated animals [62].  
Animals that have undergone uretic ligation/UUO rapidly develop tubulointerstitial 
fibrosis compared to sham operated animals. Interstitial macrophage infiltration and an expansion 
of a-SMA positive myofibroblasts play key roles in fibrogenesis in UUO animals. PTX treatment 
in UUO rats exhibited anti-fibrotic effects by decreasing accumulation of ED-1 positive 
macrophages and a-SMA positive myofibroblasts which remain elevated in UUO rats  [61]. 
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Compared to UUO rats PTX also diminished interstitial damage, as well as, interstitial collagen 
deposition, which were assessed by PAS and Masson trichrome staining respectfully [61]. 
Moreover, in UUO/PTX rat kidneys, CTGF and collagen I (a1) gene expression were also reduced 
relative to levels in untreated UUO rats [61].  
The renoprotective/anti-proteinuria effects of PTX have also been demonstrated in several 
clinical studies in patients with type I and II diabetes [63-66]. Particularly, in a randomized trial 
using 40 type II diabetic patients treated for 16-weeks with 400 mg of PTX daily, 
microalbuminuria decreased significantly from 8.4 ± 4.9 mg/mmol urine creatinine to 2.2 ± 2.6 
mg/mmol urine creatinine by the end of the treatment period [66]. Whereas, microalbuminuria 
decreased slightly from 8.5 ± 4.9 mg/mmol urine creatinine to 7.9 ± 4.7 mg/mmol urine creatinine 
in placebo treated patients, which did not reach significance [66]. These patients were non-
hypertensive and therefore not on ACEi or ARBs. In 2010, a phase IV clinical trial was initiated 
to investigate the renoprotective effects of PTX coupled with angiotensin receptor blockade using 
Valsartan, this study is expected to be completed in December 2018 [67]. Primary and secondary 
outcome measurements for this clinical trial include: doubling of serum creatinine or development 
of ESRD (primary) or changes in microalbuminuria/proteinuria, or the development of heart 
failure or stroke (secondary) [67].  
 
The Tranilast analog FT011/SHP-627 reduces TGF-b induced ERK1/2 activity 
As previously outlined, TGF-b signaling is transduced canonically via SMADs. However, 
branches of the mitogen activated kinase (MAPK) signaling pathway are also activated by TGF-
b signaling. In particular, TGF-b can exert its effects through the activation of the extracellular 
signal-regulated kinase 1/2 (ERK1/2) branch of MAPK signaling [68]. Hence, another strategy to 
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attenuate the damaging effects of overactive TGF-b can be achieved through targeting TGF-b 
induced ERK1/2 activation. Tranilast which is proposed to inhibit TGF-b activity and is used for 
the treatment of allergies and fibrotic skin disorders such as keloids has also demonstrated anti-
fibrotic activity in other tissue types [69]. Chemical synthesis of the Tranilast analog, FT011/SHP-
627, however, was prompted due to the high doses of Tranilast needed to exhibit anti-fibrotic 
effects, which ultimately compromised kidney and liver function [70, 71]. In comparison to 
Tranilast, FT011/SHP-627 demonstrated superior anti-fibrotic actions with improved in vivo 
activity and an attractive metabolic profile [70, 72]. 
FT011/SHP-627 has been evaluated in heart and kidney cells and tissues. Following 
overnight serum starvation in 0.5% fetal bovine serum, primary rat cardiac fibroblasts pre-treated 
with increasing doses of FT011/SHP-627  (10, 30, 100 µM) for 4 hours and later stimulated with 
10-7 ng/ml of angiotensin II for 15 minutes, displayed a dose-dependent decrease in levels of 
phosphorylated-ERK1/2 [72]. Additionally, primary rat cardiac fibroblasts pre-treated for 4 hours 
with 30 µM FT011/SHP-627  (also following overnight serum starvation in 0.5% fetal bovine 
serum) were significantly protected from high levels collagen type III expression after being 
stimulated with 10 ng/ml TGF-b1 for 5 minutes [72]. Cardiomyocytes from streptozotocin-
induced diabetes in Ren-2 rats treated with FT011/SHP-627  (200 mg/kg/day for 6 weeks) 
demonstrated significantly reduced nuclear staining of p-SMAD-2 and p-ERK1/2 relative to 
vehicle treated diabetic Ren-2 rats [72].  
FT011/SHP-627 is postulated, therefore, to exert its actions further downstream via 
inhibition of the phosphorylation of TGF-b induced SMADs and TGF-b induced ERK1/2 which 
attenuates fibrosis in animal models of diabetic cardiomyopathy/diabetes-associated cardiac 
fibrosis [72, 73]. In rat mesangial cells, FT011/SHP-627  has been demonstrated to not only block 
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the actions of TGF-b and its downstream effectors SMAD2 and ERK1/2 but, FT011/SHP-627  is 
also able to block platelet-derived growth factor (PDGF) activity as well [74]. This is a useful 
observation as PDGF is reported to contribute along with TGF-b to the development of the pro-
fibrotic milieu in renal tissues [75, 76]. In a 16-week assessment of FT011/SHP-627 in diabetic 
rats, albuminuria was significantly decreased at each time-point tested [74]. Likewise, 
FT011/SHP-627 assessment in STNx rats improved GFR rates and blood pressure as well as 
reduced urinary proteins [74]. Furthermore, FT011/SHP-627 completely absolved Armanni-
Ebstein lesions in diabetic Ren-2 rat kidneys which are caused by a significant abnormal 
accumulation of glycogen protein [77].  
Using both healthy and type II diabetic nephropathy patients the safety, tolerability, and 
pharmacokinetics of FT011/SHP-627  was tested in a three-part Phase I clinical trial conducted in 
Australia by Fibrotech Therapeutics which was acquired by Shire in 2014 [78]. In the first phase, 
5 different cohorts of healthy patients received single doses of FT011/SHP-627 ranging between 
10-1000 mg, the patients were followed for 7 days. The second phase observed the effect of food 
on 100 mg doses of FT011/SHP-627 while, the third phase tested the effects of increasing doses 
of FT011/SHP-627 on healthy and diabetic patients for two weeks. The pharmacokinetic profile 
of FT011/SHP-627 in these human Phase I trials included an approximately 12-hour half-life and 
clearance over 24 hours, therefore, FT011/SHP-627 would be amenable to evaluation in Phase II 
clinical trials. Additionally, FT011/SHP-627  is also being considered for evaluation in treating 
focal segmental glomerulosclerosis; Phase I formulation and dose studies and Phase II studies were 
expected to commence in 2016 and 2017, respectively [79].  
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Simtuzumab/AB0023 neutralizes LOXL2 activity 
Novel therapeutics that target excessive ECM accumulation have also been identified and 
evaluated in both in vitro and in vivo studies. For instance, Simtuzumab (a humanized monoclonal 
antibody; AB0023) neutralizes lysyl-oxidase like protein 2 (LOXL2) activity. LOXL2 is an 
important target in the treatment of fibrosis because it catalyzes covalent bond formation between 
collagen monomers [5, 14]. Further, relative to healthy controls, pathological levels of insoluble 
collagen are observed in fibrotic tissues along with increased levels of LOXL2 expression [80]. In 
particular, LOXL2 expression has been detected in liver fibrosis induced by hepatitis C infection 
or steatohepatitis in humans [80]. Evidence from preclinical studies show that LOXL2 
neutralization confers protection against the development of fibrotic and cancerous lesions. For 
instance, compared to untreated mice with liver fibrosis (carbon tetrachloride induced) a 
significant reduction in p-SMAD-3 signaling was observed after Simtuzumab/AB0023 therapy (30 
mg kg-1 twice per week during a 22-day treatment window) [80].  Furthermore, TGF-b1 and other 
mediators such as endothelin-1, CXCL12, and LOXL2 implicated in fibrogenesis decreased with 
Simtuzumab/AB0023 therapy in animal models of bleomycin induced lung fibrosis [80]. 
Bleomycin induced fibrotic lungs after Simtuzumab/AB0023 therapy also show a reduction in the 
abnormal abundance of cross-linked collagenous matrix [80]. 
Likewise, Simtuzumab/AB0023 inhibited the production of cross-linked collagenous 
matrix in the stroma of animals with tumors (MDA-MB-435 induced). As well as, significantly 
reduced the pathological abundance of growth factors such as TGF-b, VEGF-A, CXCL12, and 
CTGF in the stroma of these tumors [80]. Gilead Sciences, Incorporated funded a Phase II clinical 
trial to assess the efficacy and safety of Simtuzumab/AB0023 in patients with IPF diagnosed at 
least 3 years prior to screening (IPF average survival rate is 2-3 years) [81]. Baseline levels of 
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serum LOXL2, forced vital capacity (FVC), and pirfenidone or nintedanib therapy were used to 
stratify treatment groups and 125 mg/ml of Simtuzumab/AB0023 was given subcutaneously once 
a week to IPF patients over an event driven treatment timespan [81]. The clinical trial was 
ultimately terminated early due to failure to meet primary outcome efficacy measures 
(progression-free survival) [81, 82].  Reasons posited for lack of efficacy include LOXL family 
members, as well as, other cross-linking enzymes (e.g. Transglutaminase 2) that are not sensitive 
to Simtuzumab/AB0023 neuralization. Lack of efficacy was also attributed to insufficient drug 
exposure and/or drug delivery across fibrotic lung tissues [81]. Additional therapies to block the 
synthesis of collagen and its conversion from procollagen are also being tested for application 
towards treating fibrotic disease. An example of this strategy is UK-421,045 which targets Bone 
Morphogenetic Protein 1, a metalloproteinase, that catalyzes the conversion of soluble pro-
collagen to insoluble collagen [14]. 
 
ROCK and FAK inhibitors target the damaging effects of TGF-b 
Agents that target TGF-b induced myofibroblast proliferation or that target activation of 
fibroblasts are essential in the anti-fibrotic therapeutic toolkit. ROCK (Rho-associated coiled-coil 
forming protein kinase) and FAK (focal adhesion kinase) inhibitors that block the cellular 
signaling required for a-SMA expression have been tested preclinically as a strategy to impede 
fibroblast to myofibroblast differentiation [14]. Of note, ROCK ablated mice subjected to pressure-
overload cardiac hypertrophy are protected from the development of perivascular and interstitial 
fibrosis [83]. Additionally, in the unilateral ureteral obstruction (UUO) animal model of fibrosis, 
the ROCK specific inhibitor, Y-27632, exhibited efficacy in significantly decreasing pathological 
levels of a-SMA, TGF-b, and collagen a1(I) gene expression 10 days after UUO surgery [84]. 
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Suppression of a-SMA by Y-27632 was similar in vitro, however, suppression of TGF-b and 
collagen a1(I) were not significantly suppressed in vitro [84]. Furthermore, Y-27632 treated UUO 
animals upon histological examination revealed significantly decreased levels of a-SMA [84].   
Moreover, in vitro experimentation revealed that Y-27632 was ineffective at inhibiting mouse 
renal fibroblast proliferation although macrophage migration upon histological examination was 
diminished [84]. Lastly, Y-27632 significantly reduced interstitial expansion in UUO animals 
which was assessed by Masson’s Trichrome staining 10 days after surgery [84].  
It has been reported that in order to incite a successful fibroblast to myofibroblast 
transdifferentiation program in fibrotic tissues, overactive TGF-b requires FAK activation [85, 
86]. Immunohistochemical analysis of biopsies from patients with IPF or connective tissue 
disease-associated lung fibrosis revealed upregulated expression of FAK in myofibroblast foci and 
in remodeled arteries in fibrotic lungs [87]. Additionally, compared to embryonic fibroblast 
isolated from wild-type mice, FAK ablated mouse embryos exhibit resistance to endothelin-1 
induced FAK activation and fibrosis [87]. More specifically, FAK ablated cells were unresponsive 
to endothelin-1 induced expression of type I collagen and a-SMA which thereby impaired the 
myofibroblast differentiation program [87]. Preclinical studies in animals with bleomycin induced 
lung fibrosis revealed attenuated fibrogenesis in animals undergoing twice daily FAK inhibitor/PF-
562271 therapy at 15 mg/kg for three weeks [87].  
Several strategies aimed at targeting the TGF-b system either directly or indirectly have 
been outlined in this section. The preclinical and clinical results from these studies have been 
detailed as well. Through these studies, significant advances in the understanding of the molecular 
and cellular events that drive fibrogenesis have been realized, which yielded innovative medical 
breakthroughs for the treatment of pulmonary fibrosis.  Yet and still, a dearth of precise treatment 
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options for patients with organ fibrosis such as kidney fibrosis exists. It should also be noted that 
many of the drugs discussed in this section possess complex mechanisms of action and likely have 
targets beyond the TGF-b system.  In support of this reality, the currently approved medications 
for the treatment of pulmonary fibrosis, Pirfenidone (EsbrietÒ; Genentech) and Nintedanib 
(OFEVÒ; Boehringer Ingelheim Pharmaceuticals), are insufficient at completely halting the 
progression of pulmonary fibrosis; for example, Nintedanib can only slow disease progression for 
up to 3-years [88-90]. These outcomes likely highlight the complex nature and unknown 
mechanisms of action of these drugs. Therefore, additional strategies and novel agents with direct 
targets are needed to bolster the repertoire of anti-fibrotic therapeutics for fibrosis of the kidney 
and other organs such as the lungs and heart.  
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Table 1.1 Compounds that directly or indirectly target the TGF-b system for inhibition. 
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Table 1.2 Antibodies that directly or indirectly target the TGF-b system for inhibition. 
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Stimulation of Bone Morphogenetic Protein signaling to treat fibrotic kidneys 
 
Another strategy emerging to potentially treat fibrotic diseases is stimulation of Bone 
Morphogenetic Protein (BMP) signaling. Critical investigations have uncovered the functional 
capacity of BMP signaling to antagonize the pro-fibrotic activity of TGF-b  in several cellular 
contexts [91, 92]. Intriguingly, BMPs are a subfamily of the TGF-b superfamily of growth factor 
cytokines and a variety of tissue types depend on BMP signaling for proper development. Animals 
with genetically excised components of the BMP signaling pathway display severe developmental 
defects or die soon after birth. For instance, neonatal kidneys with genetically excised BMP7 
nearly lack glomeruli due to failed mesenchymal cell differentiation [93]. BMP7 excised 
embryonic kidneys also show abnormalities in the expression of key markers of nephrogenesis 
such as Pax2 and Wnt4 at 12.5- and 14.5-days post coitum [93]. This evidence revealed the key 
role of BMP7 in kidney development and more precisely its crucial role as an early inducer of 
glomeruli maturation [93]. BMP10, on the other hand, is essential for maintaining the proliferative 
capacity of cardiomyocytes [94]. Fittingly, embryonic BMP10 ablated cardiac tissues harbor 
excessive levels of the negative cell cycle regulator, p57kip2 [94].   As a result, BMP10 deletion in 
animals stalls cardiac tissue maturation which is embryonically lethal [94]. Deficient expression 
levels of key cardiogenic transcriptional factors involved in patterning, NKX2.5 and MEF2C, are 
also apparent in BMP10 ablated cardiac tissues [94]. Proper lung tissue development is also 
compromised upon deletion of SMAD-1, a key component of the BMP signaling pathway [95]. 
SMAD-1 conditionally ablated lung epithelial cells display differentiation and proliferation defects 
[95].  Furthermore, conditionally ablated SMAD-1 mice also exhibit arrested lung branching and 
ultimately succumb to neonatal lung failure a few hours after birth [95].  
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Over 30 BMP ligands have been identified in humans along with an array of type I 
(Alk1/2/3/6) and type II (BMPR2, ACVR2A/B, AMHR2) BMP receptors (figure 1.2) [96]. BMP 
transmembrane signal transduction once initiated is carried out by critical molecular events. First, 
BMPs are secreted and cleaved before forming hetero or homo dimers. Next, the dimerized ligand 
engages with a heterotetramer of two type I BMP receptors and two type II BMP receptors (figure 
1.2). Type II BMP receptors then phosphorylate the glycine/serine-rich domains of the type I BMP 
receptors (figure 1.2). Once the type I BMP receptor is activated, it phosphorylates SMADs-
1/5/8/9 (figure 1.2). SMADs are key intracellular transducers of canonical BMP signaling. 
Activated SMADs form a complex with a common-SMAD4 (co-SMAD4) which gains the 
capacity to translocate to the nucleus and complex with tissue specific transcription factors that 
subsequently drives target gene transcription (figure 1.2).  
The intensity and duration of BMP signaling can be fine-tuned by both intracellular and 
extracellular molecular mechanisms and regulators. Intracellularly, inhibitory-SMADs (I-
SMADs-6/7) compete with co-SMAD4 for access to activated SMADs-1/5/8/9 which 
subsequently suppresses BMP signaling (figure 1.2). Similarly, secreted proteins such as Noggin 
and Chordin negatively regulate BMP signaling using an extracellular mechanism of BMP ligand 
binding sequestration to ultimately quell BMP signaling (figure 1.2) [97, 98].  In contrast, secreted 
Kielin/Chordin-like proteins (KCP) enhance BMP signaling via stabilization of ligand:receptor 
interactions (figure 1.2) [99].  
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Figure 1.2 Schematic of the canonical BMP signaling pathway. 
Cleaved and dimerized BMP ligands initiate the canonical BMP signaling cascade by engaging 
with a heterotetramer comprised of two type I BMP receptors and two type II BMP receptors. 
Once the heterotetramer is liganded, the type II BMP receptors phosphorylate the glycine/serine-
rich domains of the type I BMP receptors. Activated, the type I BMP receptor phosphorylates 
SMADs-1/5/8/9, which are key intracellular transducers of canonical BMP signaling. Key aspects 
of the BMP signaling pathway are regulated by both extracellular and intracellular molecules. 
Secreted proteins like Noggin and Chordin inhibit BMP activity whereas, Kielin/Chordin-like 
proteins (KCP) enhance BMP activity. Intracellular proteins such as I-SMADs-6/7 compete with 
co-SMAD-4 for access to receptor activated SMADs-1/5/9, which suppresses BMP signaling.  
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 Extensive studies have been undertaken to demonstrate the beneficial effects of BMP 
signaling activation in animal models of kidney disease [91, 100-102]. Complete understanding of 
the mechanisms underlying the beneficial actions of BMP signaling in the fibrotic kidney however, 
still remains elusive [103, 104]. Recombinant BMP2 and BMP7 are currently FDA approved for 
clinical use in bone disorders [96]. However, harmful doses of BMPs are needed to achieve 
efficacy and recombinant BMPs are both complex and expensive to synthesize with a single 
therapeutic dose costing $5,000 [105-107].  
KCP proteins, as highlighted above, promote enhanced BMP signaling and exhibit 
beneficial effects in fibrotic kidney tissues.   Contralateral and UUO kidneys harvested at 1, 2, or 
4 weeks from transgenic KCP expressing mice, exhibit strong levels of p-SMAD-1 expression as 
detected by immunoblotting [99]. Conversely, contralateral and obstructed kidneys harvested at 
the timepoints stated above from KCP deficient animals exhibit suppressed BMP signaling as 
assessed by a marked reduction in p-SMAD-1 expression [99].  In these same studies, a-SMA 
assessed interstitial fibrosis and collagen deposition were far more pronounced in KCP deficient 
animals compared to wild-type UUO kidneys [99].  Pathological expansion of activated fibroblasts 
was also 2-fold higher in UUO kidneys from KCP deficient mice at 7 and 13 days after obstruction 
compared to wild-type UUO kidneys harvested at comparable stages [99]. Inversely, studies in 
transgenic animals overexpressing KCP revealed a less severe response to acute and chronic 
kidney injury compared to wild-type animals [108]. Notably, overexpressed KCP has similar 
protective effects in animal models of non-alcoholic fatty liver disease and diet-induced obesity 
[109, 110].  KCP proteins contain 1,254 amino-acids and 18-cysteine rich domains.  Thus, large 
scale synthesis of KCP for clinical anti-fibrotic use is precluded by its size and complexity [99]. 
Small-molecules, however, that are easier to synthesize and more cost-effective to produce may 
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provide an alternative strategy to exogenously enhance BMP signaling relative to large scale 
production of BMP and KCP recombinant proteins.  
To employ the beneficial effects of BMP activity in several disease contexts, identifying 
novel small-molecules that stimulate BMP signaling is of interest. Bone disease investigators have 
identified small-molecules that have the capacity to enhance BMP signaling and induce osteoblast 
activity and differentiation [111-114]. Likewise, for potential application towards 
medulloblastoma treatment, researchers have also identified several molecules that activate BMP 
signaling as assessed by: increased levels of p-SMAD-1/5/8 signaling, ventralized zebrafish 
embryos, activation of direct BMP4 gene targets, and osteoblast differentiation from myoblasts 
[115, 116]. Even more, application of FK506 for the treatment of pulmonary hypertension has 
been explored and found to enhance BMP signaling as assessed by activated SMAD-1/5 and ID1, 
as well as, MAPK (non-canonical BMP signaling) [117]. Chemical sensitizers of BMP signaling 
to achieve directed stem cell differentiation have also been described. Reports show these BMP 
sensitizers are able to induce human embryonic stem cells towards mesoderm or cytotrophoblast 
linages, as well as, osteoblast linages  [118, 119].  
Identification of a small-molecule that induce heterotetramerization and activation of type 
I and type II BMP receptors exactly as BMP ligands has not been reported. Although the 
immunosuppressants, Sirolimus (Rapamycin) and Tacrolimus (FK506), have been identified as 
agents with the capacity to activate type I BMP receptors by liberating the glycine/serine-rich 
domains of type I BMP receptors from FKBP12 inhibition [117, 119]. Importantly, potent and 
selective small-molecule inhibitors of BMP signaling have also been identified and include: 
dorsomorphin [120], dorsomorphin homolog 1 (DMH1) [121], and LDN-193189 [122]. These 
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inhibitors block the kinase domain of type I BMP receptors and prevent ATP-pocket binding which 
results in suppressed BMP signaling.   
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Reactivation of the nephrogenic regulator, Pax2, in kidney cancer  
 
Kidney cancer is another major contributor to ESRD. In the United States, an estimated 
73,820 new kidney cancer patients will need treatment and 14,770 patients will succumb to kidney 
cancer in 2019 [123]. Worldwide, 403,262 new kidney cancer cases along with 175,098 patient 
deaths were documented in 2018 [124]. Between 1975-2012 mortality rates for kidney and renal 
pelvis cancer remained steady [125]. Incidence rates from 1975-2008, on the other hand, initially 
spiked but, have plateaued over the last decade [125-127]. Key risk factors for kidney and renal 
pelvis cancer include obesity, hypertension or its treatment, chronic use of NSAIDs, smoking, and 
environmental/work related factors [125, 128]. The 5-year relative survival rate for localized 
kidney and renal pelvis cancer is 73% [125]. Unfortunately, however, the 5-year relative survival 
rate for metastasized kidney and renal pelvis cancer is at a dismally low 11.6% [125]. 
Clear-cell Renal Cell Carcinomas (ccRCC) are the most common type of adult kidney 
cancer and 90% of kidney cancer patients are diagnosed with this subtype [129]. ccRCC develops 
in the nephrons of the kidneys, which are the key filtration units that ensure proper cleansing of 
systemic blood. The nephrons consist of a glomerulus and its associated proximal and distal 
tubules. ccRCC develops in the proximal tubule epithelial cells the most abundant cell type in the 
kidney. The majority of ccRCC have von-Hippel-Lindau (VHL) gene inactivating mutations, 
which can be inherited or sporadic [7, 130, 131]. VHL is part of a complex that harbors E3 
ubiquitin ligase functional activity. Normoxia promotes tight VHL regulation of hypoxia-inducible 
factor-1a (HIF-1a) which is upregulated in response to hypoxic or ischemic conditions [132]. 
Mutated VHL, therefore, lacks the functional capacity to ubiquitinate HIF-1a which prevents 
targeting of HIF-1a to the proteasome for degradation. Deregulated and stabilized HIF-1a is 
therefore able to translocate into the nucleus and dimerize with constitutively active HIF-1b. The 
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aberrantly functional HIF-1ab transcriptional complex consequently activates an abundance of 
HIF-1ab target genes, which become pro-oncogenic under the deregulated HIF-1a signaling 
cascade. Important mediators driving malignant behavior include HIF-1a gene targets vascular 
endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR).  
The paired-homeobox 2 (Pax2) protein is reported to be negatively regulated by VHL and  
a significant correlation between Pax2 and HIF-1a in ccRCC has been demonstrated in patient 
tumors [133]. Immunohistochemical analysis revealed that of 294 Pax2-positive patient tumors, 
222 also expressed HIF-1a [133]. Nearly all ccRCC possess reactivated Pax2 that is required to 
sustain proliferative and malignant tumor behavior [134]. Expression of Pax2 is also observed in 
Wilms’ tumor and often in ovarian cancer [135]. Pax2 is a critical transcription factor upregulated 
during and required for normal kidney development and the female reproductive tract [136]. As 
such, homozygous Pax2 deficient animals lack kidneys while animals with overactive Pax2 
acquire dysfunctional renal epithelial tissues [136, 137].  
Upregulated Pax2 during development is required for the crucial step needed to convert 
mesenchymal cells into epithelial cells in emerging nephrons. However, Pax2 repression is needed 
as emerging nephrons are maturing to achieve fully differentiated and functional renal epithelium 
[137, 138]. Therefore, once nephrogenesis is fulfilled, mature nephrons terminate Pax2 expression 
in each of its epithelial lined compartments (i.e. glomerulus and its associated proximal and distal 
tubules) [133, 139]. Pax2 reactivation has been observed in both kidney injury and ccRCC [134, 
140]. Downregulation of Pax2 expression by antisense oligonucleotides, however, arrested growth 
and proliferation of kidney tumor cells [134].  
Current treatment strategies for ccRCC include total or partial nephrectomy. However, 
roughly 30% of these patients will still develop metastatic spread of cancerous cells [129]. At the 
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time of nephrectomy, patients with low-, intermediate-, and high-risk metastatic renal cell 
carcinoma have 5-year survival rates of 41%, 18%, and 8% respectively [141]. Moreover, partial 
nephrectomy treatment can lead to ESRD which requires dialysis or kidney transplantation. A 
significant panel of first- and second-line targeted therapeutics exist to treat metastatic ccRCC, 
such as VEGF mTOR inhibitors [127]. However, resistance continues to be an obstacle in 
achieving effective long-term therapy and increasing survival rates [142]. Therefore, the 
development of novel therapeutics and treatment strategies are warranted.   
As stated previously, Pax2 is a transcription factor that is ectopically expressed in ccRCC 
and Pax2 can be identified in metastasized tumors [143]. Thus, small-molecule inhibitors of Pax2 
transcription activity could provide novel treatments for ccRCC patients. Nuclear transcription 
factors such as Pax2 lack a ligand binding pocket which deemed Pax2 an undruggable target.  
However, using in silico methods to identify small-molecules with the capacity to inhibit Pax2 
DNA binding activity and follow-up analog assays, an encouraging study identified a small-
molecule, EG1, that inhibits  Pax2 activity [144]. This study demonstrated an up to 75% reduction 
of Pax2 mediated branching morphogenesis in cultured kidney rudiments harvested at e11.5 and 
treated for 2 days with 50 µM EG1. Incomplete aggregation of Pax2+ cells at ureter tip buds was 
also observed in EG1 treated cultured kidney rudiments [144]. A Pax2+  renal cell carcinoma cell 
line (RCC111) also displayed decreased cell proliferation and viability after treatment with EG1 
[144].  Furthermore, a 3-hit mouse model to study renal cell carcinoma was also recently developed 
and these animals and their cells can be used to test small-molecules like EG1 that inhibit Pax2 
transactivation [131]. 
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Pax2 transactivation in cystic kidney epithelial cells   
 
Dysregulated Pax2 activity is also documented in Polycystic Kidney Disease (PKD) [145]. 
In PKD, epithelial cells lining the renal tubules become cystic and progressively dilate which leads 
to enlarged kidneys or nephromegaly, and eventual ESRD [146]. PKD is the fourth leading known 
primary causes of ESRD in the United States and can be inherited in either an autosomal dominant 
or autosomal recessive manner [147, 148]. PKD development via de novo mutations is also 
reported at considerable rates [147]. Mutated genes that cause autosomal dominant PKD include 
polycystins (PC1 or PC2) whereas mutations in polycystin kidney and hepatic disease I (PKHD1) 
cause autosomal recessive PKD [147]. Autosomal dominant PKD is the most common monogenic 
disorder among adults, approximately 1/400-1/1000 cases are reported each year while,  1/10,000-
40,000 cases are reported for the much rarer autosomal recessive form of PKD [147, 149].  
In both mice and humans, cystic epithelial cells of the renal tubules harbor ectopic Pax2 
expression [137, 145, 150]. In cystic animal kidneys that possess only one Pax2 allele, arrested 
cystogenesis is observed and animals survive for 4-6 weeks after birth [151]. Notably, increased 
apoptotic events are observed in kidneys with reduced Pax2 expression during normal kidney 
development in both mice and humans [151].  In contrast, kidneys in diseased animals harboring 
two Pax2 alleles have large cysts and animals die within 3 weeks of birth [151]. 
No curative therapies for PKD exist, however, the current standard of care is management 
of hypertension with ACEi or ARBs as a first line therapy [147]. Therefore, novel-small molecules 
with the functional capacity to inhibit Pax2 activity specifically in renal tubular epithelial cells 
could potentially slow disease progression. Preclinical testing of small-molecule inhibitors of Pax2 
in animal models of PKD including human xenograft animal models of PKD will aid in the 
identification of novel therapeutics for PKD.  
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Chapter 1 Summary and Conclusion 
 
Chronic Kidney Disease constitutes a serious global health burden where reported cases 
are steadily rising and encompass fibrosis, cancer, and cystic disease of the kidney. Kidney fibrosis 
manifests as loss of epithelial tissues and vascular supply. Whereas, kidney cancer results in 
increased proliferation of epithelial tissues and increased vascular supply. Cystic kidney disease 
also presents with an increased proliferation of cystic epithelial cells. Given the array of factors 
that can cause CKD and lead to ESRD, limited therapeutic options exist although multiple novel 
agents are being explored. Overall, developing effective and targeted therapeutics that will aid in 
the repair and regeneration of damaged and diseased tissues will help reduce the global health 
burden of CKD.  
Embryological tissues designated as the intermediate mesoderm generate the ureteric bud 
and mesenchyme tissues that ultimately form adult kidneys. Key in the development of adult 
kidneys is the critical process of mesenchymal cell differentiation into epithelial cells from which 
nephrons arise. Dysregulation of developmental molecules that coordinate the induction of 
mesenchymal-to-epithelial transition are implicated in pathological processes that drive kidney 
disease. As highlighted in this chapter, bone morphogenetic proteins have essential roles in normal 
kidney development. Animals deficient in BMP7 essentially fail to generate glomeruli due to 
unsuccessful mesenchymal cell differentiation and  abnormal expression patterns of key markers 
of nephrogenesis such as Pax2 and Wnt4 are apparent [93].  
Activation of BMP signaling has been reported to be protective in animal models of fibrosis 
or chronic kidney disease by promoting repair and regeneration of damaged kidney tissues. In 
contrast, TGF-b drives fibrogenesis and the TGF-b signaling system can be targeted for inhibition 
at multiple levels (i.e. mature ligands, receptors, etc.). Hence, combinatorial molecular tools that 
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aim to suppress TGF-b signaling while simultaneously activating BMP signaling may provide new 
therapeutic strategies to treat chronic kidney disease. 
As with BMPs, Pax transcription factors have an absolutely essential role in kidney 
development. Homozygous Pax2 deficient animals lack kidneys as Pax2 is required for renal 
mesenchymal-to-epithelial transition [136]. Mature kidney epithelial tissues silence Pax2 gene 
activity. However, in mice and humans, ectopically expressed Pax2 expression is observed and 
correlates with kidney cancer and cystogenesis progression. Reduction of Pax2 activity in animal 
models slows the progression of renal cell carcinoma and cystic kidney disease.  
This dissertation describes experimental efforts toward identifying novel small-molecules 
that stimulate Bone Morphogenic Protein signaling, As well as, efforts that attempt to identify 
small-molecules that inhibit the transcriptional activity of Pax2. The purpose of these efforts are 
to ultimately test the potential efficacy of these small-molecules in animal models of various 
subtypes of chronic kidney disease, which include fibrosis and proliferative disorders such as 
cancer and cystic kidney disease.   
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 - Kidney Fibrosis: HTS for small-molecule agonists of BMP signaling 
 
Abstract 
 
High-throughput screening (HTS) is a common methodology utilized in industry and 
academic settings to carry out drug discovery programs. Millions of diverse chemical structures 
can be rapidly screened to yield drug/lead-like compounds that can be optimized for pre-clinical 
studies and clinical trials. Cell-based HTS assays in particular offer the advantage of screening 
compounds in an intact cellular environment. This feature of cell-based HTS aids in discovering 
chemical structures with not only potential extracellular activity but also possible intracellular 
activity due to their capacity to penetrate cellular membranes. This is in contrast to biochemical 
HTS assays that may not yield a drug/lead-like compound that is biologically active in an intact 
cellular environment. Cell-based HTS methods can be applied toward meeting the unmet clinical 
need for targeted therapeutics to treat chronic kidney disease or kidney fibrosis. To launch any 
drug discovery project the first step is to identify a drug target or pathway implicated in the disease. 
At least two decades of research have pointed toward the renoprotective benefits of BMP signaling 
in animal models of acute and chronic kidney disease. This chapter will discuss academic drug 
discovery efforts to identify small-molecules that activate BMP signaling in renal cells using HTS 
methodologies.  
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Introduction 
 
A key methodology in the quest for novel drugs to treat disease is the use of high-
throughput screening (HTS). HTS allows up to millions of drug/lead-like small-molecules to be 
screened for biological activity in a relatively short period of time and is the most widely used 
technology to identify drug/lead-like molecules  [1, 2]. Cell-based HTS assays, in particular, offer 
the advantage of testing potential drugs in an intact cellular environment. Therefore, cell-based 
HTS improves the prospects of identifying biologically relevant drug/lead-like compounds [1]. 
Whereas biochemical HTS assays, where the target is isolated, may prove futile in this regard. A 
disadvantage of cell-based HTS, however, is that the direct binding target of the compound 
identified is unknown. In contrast, this is a powerful aspect of mechanism-based biochemical 
assays. Therefore, additional experimentation would be necessary in order to identify direct 
binding targets of small-molecules identified in cell-based HTS. Follow-up optimization of 
biological activity and minimization of off-target effects of the compound would be feasible by 
such efforts.  
Reporter gene systems are heavily used in cell-based HTS assays and monitor the 
expression of pathway genes linked to enzymes such as luciferase [1]. Luciferase-based reporter 
assays in particular offer sensitivity and a sizeable dynamic range, as well as rapid results [1]. 
Several disadvantages of luciferase-based HTS however, have been described. Some of these 
disadvantages are inherent to the process of screening large chemical libraries with diverse 
structures of small-molecules. In particular, many libraries contain small-molecules that interfere 
with the luciferase assay because they are structurally similar to the natural substrate of firefly 
luciferase, D-luciferin [3, 4]. Reports have described a phenomenon by which such small-
molecules stabilize the firefly luciferase protein and prevent its degradation which ultimately leads 
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to increased luminescence detection [3-5].  Some chemical series that have been reported to behave 
in this way include: quinolines, 1,2,4-oxadiazoles, benzthiazoles, benzimidazoles, and 
benzoxazoles [3, 4]. However, it is important to note that some small-molecules that inhibit an 
enzymatic reporter such as luciferase may still possess relevant biological activity, such as 
resveratrol [3, 6]. Moreover, several compounds that are currently being marketed possess a 
benzoxazole core moiety such as: funoxaprofen, benoxaprofen (nonsteroidal anti-inflammatory 
drugs), calcimycin (antibiotic), boxazomycin B (antibacterial), and chloroxazone (muscle 
relaxant) [7]. 
HTS technology can be applied towards discovering medicines that can alleviate chronic 
kidney disease or renal fibrosis. Cell-based HTS assays in particular can be used to identify small-
molecules with novel mechanisms of action that can potentially activate pathways that play a role 
in tissue regeneration and repair such as BMP signaling. Furthermore, development of small-
molecules for clinical use offers many advantages and include: low cost, relatively long shelf-life, 
reversible and rapid activity, as well as, spatial and temporal control [8]. 
Histologically, chronic kidney disease manifests as kidney fibrosis [9]. Meaning, injured 
functional structures and compartments of the kidney such as the nephron, its surrounding capillary 
supply, and the tubulointerstitium are overcome with excessive ECM deposition [10]. Under 
fibrotic conditions, TGF-b provokes interstitial fibroblasts to proliferate, turn contractile, and 
deposit excessive ECM in the renal parenchyma [11]. Early on in renal fibrosis, pro-apoptotic 
stimuli such as ischemia triggers hypoperfusion and peritubular capillary rarefaction, which is 
worsened later by an expanding ECM filled renal parenchyma [12-14]. Tubules of nephrons once 
tightly pack together with narrow interstitial spacing and few fibroblasts surrounding them atrophy 
due to apoptosis and/or necrosis [15]. Furthermore, excessive ECM deposition contributes to the 
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expansion of nonfunctional tissue in the renal interstitium [16]. Moreover, inflammatory lesions 
are additional key features of diseased renal tissues in the fibrotic milieu  [17]. 
While extensive evidence has implicated overactive TGF-b1 as the principle molecular 
driver of fibrogenesis in the kidney in both mouse and man. Pre-clinical and clinical studies have 
also highlighted dysregulated BMP7 signaling as another key characteristic of fibrotic kidneys. 
Specifically, animals with ischemic acute renal failure [18], unilateral ureteral obstruction [19], 
diabetic nephropathy [20, 21], or genetic forms of chronic kidney disease [22],  exhibit 
significantly decreased levels of BMP7 relative to the 0.1-0.5 ng/ml of normal circulating levels 
of BMP7 in healthy animals [18]. However, in human proximal tubular epithelial cells from 
patients with proteinuric nephropathies, BMP7 is upregulated approximately 4 fold compared to 
controls [23]. Other studies in human diabetic nephropathy noted decreased expression of BMP7 
and BMP signaling in the glomerular compartment, specifically, in podocytes, which maintain the 
filtration barrier [24, 25].  
Reinduction of suppressed BMP signaling has been demonstrated to be protective in animal 
models of acute and chronic kidney injury. Acute kidney injury is a risk factor of chronic kidney 
disease and ischemia is a common primary cause of acute kidney injury in adults [26-28]. Several 
damaging changes in the kidneys occur following ischemia and reperfusion injury.  In particular, 
ischemia and reperfusion induced injury to the kidneys include: tubular apoptosis and necrosis, 
inflammatory lesions, as well as, abnormal levels of blood urea nitrogen and serum creatinine.  
In rat kidneys injured by bilateral artery occlusion for 60 minutes, systemic administration 
of 250 µg/kg BMP7 was shown to stimulate the proliferation of damaged tubular epithelial cells 
of the nephron after reperfusion [18]. This observation led to the suggestion that BMP7 promotes 
renal repair and regeneration through mechanisms that it employs during kidney development [18]. 
 56 
Since, during kidney development, BMP7 acts as a survival factor for the metanephric 
mesenchyme [29]. Specifically, BMP7 maintains and expands nephron progenitor cells by 
inhibiting apoptosis and differentiation [29]. Simultaneously, however, BMP7 stimulates the 
proliferation of nephron progenitor cells [29]. Additionally, BMP7 deficient neonatal kidneys have 
low glomeruli and nephron numbers [29]. Inflammation was also suppressed in BMP7 treated 
animals with ischemic injury, which was demonstrated by downregulated levels of ICAM-1 
(intracellular adhesion molecule-1) expression and a significant reduction in neutrophil 
accumulation [18].   Creatinine and blood urea nitrogen levels were also 8-10 times lower in BMP7 
treated animals compared to vehicle treated animals that underwent bilateral artery occlusion [18]. 
BMP7 also demonstrates several renoprotective effects in animals subjected to unilateral 
ureteral obstruction (UUO). UUO surgery in animals is a model of progressive renal fibrosis [15]. 
Albeit common in children, UUO is an unusual primary cause of adult human renal failure [15, 
30]. Nevertheless, in UUO subjected animals, upregulated TGF-b is found within 10 hours after 
surgery, which is stimulated by overactive angiotensin II [31-33]. Vasoconstriction of afferent 
renal arterioles is also induced by overactive angiotensin II in UUO animals [30, 34]. Additionally, 
within 24 hours, reduced blood flow and decreased rates of glomerular filtration are apparent in 
UUO animals [15, 34].  A few days later, hydronephrosis, macrophage induced inflammatory 
lesions in the interstitium, and demise of tubular structures from apoptosis and necrosis also occur 
[15]. Furthermore, UUO causes fibrotic lesions in the interstitium which is mediated by 
transdifferentiated renal cells into myofibroblasts which lay down excessive levels of extracellular 
matrix proteins such as collagen (I, III, IV) and fibronectin [15].   
Systemic therapy of both 100 and 300 µg/kg of BMP7, given at the time of UUO followed 
by once daily doses of BMP7 every other day, significantly reduced atrophic renal tubules induced 
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by 5 days of unilateral obstruction in rats [19]. This evidence suggested that BMP7, in a dose-
dependent manner, exerts its renoprotective effects through maintaining the integrity of the tubular 
epithelium. Importantly, the ACE inhibitor, enalapril (25 mg/kg, high dose), lacked the capacity 
to preserve tubular integrity in UUO animals [19]. Use of ACE inhibitors is a common clinical 
therapeutic strategy for patients with CKD to slow disease progression, however, many patients 
still advance to ESRD [35].  
BMP7 therapy at the initiation of UUO abated fibrotic lesions as assessed by a-SMA 
positive myofibroblasts and collagen IV [19]. Of note, BMP7 therapy at the doses tested, was 
unable to return a-SMA positive myofibroblast accumulation and collagen IV expression to 
baseline levels observed in the contralateral kidneys treated with either vehicle or BMP7. This may 
underscore the need for combinatorial strategies that simultaneously suppress pro-fibrotic TGF-
b activity, as well as, stimulate BMP7 signaling to maintain tubular epithelial integrity in diseased 
kidneys for optimal therapy. Additionally, inflammatory lesions, as assessed by macrophage 
interstitium infiltration, were significantly attenuated in a dose-dependent manner in animals 
undergoing BMP7 therapy [19]. The renoprotective effects of BMP7 in UUO animals were also 
accompanied by preserved renal blood flow which is typically decreased within 24 hours of 
surgery [19, 34].  
As demonstrated in the two seminal studies outlined above, loss of BMP7 in the tubular 
epithelium leads to cellular apoptosis and ultimately tubular atrophy in animal models of acute and 
chronic kidney disease. Loss of BMP7 is also evident in animals subjected to experimental doses 
of STZ, which models key aspects of type I diabetes induced nephropathy in humans [20, 21]. 
These animals typically develop albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis; 
however, some renal histopathological changes are species, strain, and dosing regimen specific 
 58 
[36-39]. In rats with diabetic syndrome induced by one 62 mg/kg dose of STZ, considerable 
glomerular hypertrophy at 16-weeks post STZ injection was observed in vehicle treated animals 
[21]. Twice weekly doses of 10, 30, or 100 µg/kg of BMP7 therapy commenced at week 16 post 
STZ injection and continuing until week 32, however, partially reversed this histopathological 
finding [21]. Segmental glomerulosclerosis and the accumulation of early interstitial matrix 
accumulation (assessed by collagen staining) was also reduced by BMP7 therapy in a dose-
dependent manner [21]. 
As with animal models of inducible forms of acute and chronic kidney disease, BMP7 
therapy is also beneficial in protecting animals from genetic causes of kidney failure.  Within 4 
weeks, MRL lupus mice exhibit early signs of increased interstitial volume and tubular atrophy, 
BMP7 therapy reverses these fibrosis-associated changes [22]. Glomerulosclerosis and glomerular 
hypercellularity was reduced in MRL lupus mice under 300 µg/kg BMP7 therapy [22]. 
Additionally, type I collagen levels in these mice were also decreased under BMP7 treatment [22]. 
In mice with deficient type IV collagen-a3 gene (Col4A3-/-), tubulointerstitial fibrosis and tubular 
atrophy were also diminished with 300 µg/kg BMP7 treatment [22]. Renal function in Col4A3-/-   
mice was also improved under BMP7 therapy as assessed by improvements in serum creatinine, 
blood urea nitrogen levels, and urine protein [22].  
The therapeutic effects of BMP7 in the fibrotic kidney have been demonstrated in 
numerous studies using different animal models of acute and chronic kidney disease. BMP2 and 
BMP7 are currently FDA approved for clinical use in bone repair procedures. However, several 
barriers exist in translating this therapy into clinical settings for renal disease. One barrier in the 
clinical application of BMPs is the 1.5 mg/ml doses required to achieve efficacy in human bone 
repair procedures [40]. The high therapeutic dose of BMP needed in humans is in stark contrast to 
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the potency displayed and efficacy yielded using significantly lower doses of BMPs in both cell 
culture and animal studies. In renal studies for instance, 10 and 100 ng/ml of recombinant BMP7 
sufficiently displayed a dose-dependent reduction in the synthesis of type I collagen and 
fibronectin in activated human fibroblast (TK-173) [22]. Additionally, 30-300 µg/ml of 
recombinant BMP7 was sufficient to observe dose-dependent reversal of fibrosis associated 
changes in animals with acute and chronic kidney injury [18, 19, 22]. Humans treated with supra-
physiological doses of BMPs have consequently experienced harmful side effects such as 
inflammation and ectopic bone growth [41-43].  
Another barrier in translating recombinant BMPs into clinical use is the high 
manufacturing costs associated with the complex structure of BMPs. BMPs have a distinctive 
cysteine-knot fold tertiary structure formed by six conserved cysteine residues that form three 
intrapeptide disulfide bonds [29]. Additionally, BMPs have multiple proteolytic sites and therefore 
are a heterogeneous mixture of differentially processed proteins [44]. Moreover, due to 
denaturation, BMPs possess a shorter shelf-life relative to small-molecules which are considered 
to be more stable [45]. Added drawbacks to recombinant BMP therapy for renal disease are the 
limited routes of administration, which include intravenous infusion or subcutaneous injections. 
Intravenous infusion would necessitate inpatient care while self-administered subcutaneous 
injection may prove unappealing to patients. Both routes of administration have the potential to 
hinder patient adherence, especially for chronic illnesses such as kidney disease [45]. The option 
of oral administration of BMPs may be limited do to gastrointestinal tract degradation issues [46]. 
Moreover, intravenous infusion or subcutaneous injection would add to the already high 
manufacturing costs of recombinant BMP therapies.  
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Orally active small-molecules, in contrast, can be designed to stimulate BMP signaling at 
various levels of the pathway.  In canonical BMP signaling, dimeric BMP ligands signal through 
a heterotetramer of two type I and type II BMP serine/threonine kinase receptors. BMP ligand 
binding triggers type II BMP receptors to phosphorylate the type I BMP receptors. Activated, the 
type I BMP receptor phosphorylates key intracellular transducers of canonical BMP signaling, 
SMADs-1/5/8/9. Extracellular enhancers and inhibitors regulate the bioavailability of BMP 
ligands in order to fine tune BMP signaling. While, intracellular factors such as inhibitory SMADs-
6/7 fine tune intracellular levels of BMP signaling activation. Other molecules such as Smurfs 
target SMAD proteins for degradation by the proteasome. Furthermore, TGF-b signaling and its 
effectors SMADs-2/3 heavily oppose BMP signaling.  
Using HTS methods, small-molecules have been identified that target various aspects of 
the BMP signaling pathway outlined in the previous section. These agents can be utilized for 
potential application toward a variety of BMP signaling related biological outputs. For example, 
BMPs are important regulators of stem/progenitor cell fate decisions. Additionally, BMPs are used 
for the maintenance and directed differentiation of embryonic stem cells toward different cell fates 
[47]. Therefore, cell-based HTS assays have been used to identify a BMP agonists/sensitizer for 
use in human embryonic stem cell differentiation. This particular cell-based HTS used a reporter 
construct containing the Id2 (key BMP target gene) promoter transfected into C2C12 myoblasts to 
assay more than 4,000 small-molecules. The chemical library used contained kinase inhibitors, 
signaling pathway regulators, natural products, and United States Food and Drug Administration 
approved drugs [47].  
The cell-based HTS assay yielded, PD407824, a checkpoint kinase inhibitor (CHK1), 
which was demonstrated to sensitize C2C12 myoblasts to sub-threshold levels of BMP4 treatment 
 61 
and upregulated the expression of Id1 and Id2 [47]. Furthermore, PD407824, was found to 
synergize with BMP4 to reprogram C2C12 myoblasts cells to an osteoblasts fate [47]. As well as, 
quantitatively increased SMAD-1/5/9 levels in the presence of BMP4. Mechanistic experiments 
demonstrated that PD407824 inhibition by CHK1, downregulates P21 which leads to SMAD-2/3 
degradation. This ultimately leads to increased association of SMAD-1/5/9 with co-SMAD-4, 
which leads to more effective activation of Id1 and Id2 [47].  
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Results 
 
Validation of renal BRE-Luc cells for High-Throughput Screening (HTS)  
A construct with a BMP responsive element (BRE) driving luciferase expression was 
stably integrated into the genome of human renal cells, which we termed BRE-Luc. Critically, the 
BRE-Luc construct contains distinct elements of the ID1 promoter that are necessary for p-SMAD-
1/5/9 binding (figure 2.1A) [48]. Moreover, inverted repeats of the p-SMAD-1/5/9 binding 
elements confer high sensitivity to rh-BMP4 treatment and a wide dynamic range of detection of 
activated BMP signaling. Accordingly, in luciferase assays, we observed that rh-BMP4 treatment 
caused a dose-dependent increase in luciferase activity in BRE-Lucs (EC50 = 2.405 ng/ml); 
whereas, DMSO treatment did not (figure 2.1B).  
Hence, our BRE-Luc cell line displayed a highly specific response to rh-BMP4 treatment. 
Additionally, 10 ng/ml of rh-BMP4 yielded a 10-fold increase in luciferase activity over DMSO 
(figure 2.1B). Furthermore, immunoblotting assays revealed that stimulation of BRE-Lucs with 
0.4, 2, or 10 ng/ml of rh-BMP4, yielded a dose-dependent induction of p-SMAD-1/5/9 (figure 
2.1C). With 2 ng/ml of rh-BMP4 yielding a 16-fold induction of p-SMAD-1/5/9 compared to 
untreated cells (figure 2.1D). Moreover, in the presence of increasing doses of rh-BMP4, basal 
levels of the TGF-b effectors, p-SMAD-2 and p-SMAD-3 remained virtually constant (figure 
2.2A). Our BRE-Lucs, therefore, displayed the sensitivity and specificity needed to detect 
activated BMP signaling in a renal cell-based HTS assay for small-molecule agonists of BMP 
signaling. 
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Identification of BMP signaling agonists via a renal cell-based HTS 
63,608 small-molecules from the Center for Chemical Genomics library were screened at 
a single concentration (10 µM) in renal BRE-Lucs in our primary HTS (figure 2.3A-B). After 
applying the following MScreen [49] filters: activity of small-molecules ≥ 18% activity of the 
positive control (25 ng/ml rh-BMP4) or ≥ 3 standard deviations above the negative control (0.1% 
DMSO), 1,453 small-molecules from our primary screen were selected for confirmation retesting 
in triplicate. 1,218 small-molecules confirmed.  
To select for compounds for our dose-response confirmation studies, we used the following 
criteria: activity of small-molecules ≥ 10% of the positive control (25 ng/ml rh-BMP4) and active 
three out of the four times tested. 70 compounds met these criteria and passed an additional counter 
screen for non-specific activation of our BRE-Luc construct. Fresh powders of the top sixteen 
compounds were re-ordered for dose-response studies. Twelve of the sixteen small-molecules 
displayed dose-response activity with relatively potent EC50’s (figure 2.4A-B). One compound, 
sb4, not only displayed a sigmoidal dose-response curve but also, the lowest EC50 (~74nM) of the 
top twelve compounds (figure 2.4A-B). Luciferase activity after sb4 treatment was also increased 
2.5-fold compared to DMSO at a top concentration of 1000 nM (figure 2.4B). The Hill Slope of 
sb4 was determined to be 1.24 (figure 2.4B). Of the twelve small-molecules some had similar 
structures (sb1 and sb2, sb3 and sb4, sb5 and sb6) while the remaining compounds were singletons 
with unique structures (sb-sb12) (figure 2.4C). 
  
 64 
Discussion  
 
This Chapter describes cell-based HTS methodologies that were carried out in order to 
identify small-molecules that activate the BMP signaling pathway for potential application toward 
treating Chronic Kidney Disease.  Human renal cells (HEK-293s) expressing a genomically 
integrated BMP responsive element fused to firefly luciferase were employed to screen 
approximately 64,000 small-molecules in the Center for Chemical Genomics (CCG) library at the 
University of Michigan. The primary screening campaign and triage strategies identified twelve 
compounds that activated the BRE-Luc reporter construct in a dose-dependent manner. The half 
maximal effective concentration for these top twelve BMP signaling agonists were relatively low 
and ranged from approximately 74-1249 nM. However, it is important to bear in mind that the 
BRE-Luc reporter construct is an artificial tool that is highly responsive to BMPs because it 
contains inverted repeats of critical elements of the ID1 promoter that are necessary for p-SMAD-
1/5/9 binding. Although a powerful tool for detecting subtle changes in BMP signaling, the results 
obtained from the artificial system may not translate directly when assessing endogenous levels of 
specific components of the BMP signaling pathway. 
As explained in the introduction of this Chapter, cell-based HTS offers the advantage of 
testing small-molecules in an intact cellular environment. However, key mechanistic information 
about the direct binding target is unknown. Therefore, the top twelve BMP signaling agonists 
identified may act to enhance the BRE-Luc transcriptional response through an array of possible 
novel mechanisms. These top twelve compounds could also work to activate BRE-Luc through 
unwanted mechanisms. Therefore, after conducting the primary HTS screen described in this 
Chapter, secondary assays were used to characterize and gain mechanistic insights about the top 
twelve BMP signaling agonists. The results of these secondary assays are described in Chapter 3.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Characterization and validation of BRE-Luc cells for HTS.  
(A) The BRE-Luc reporter construct contains an inverted repeat of BMP responsive elements 
driving luciferase.  Elements of the ID1 promoter and SMAD binding sites are marked as 
originally identified by Korchynskyi et al. [48].  (B) A dose-response curve of BRE-Luc cells 
subjected to increasing concentrations of rh-BMP4 performed in triplicate.  (C) Western blot of 
lysates from BRE-Luc cells treated with increasing concentrations of rh-BMP4.  Membranes 
were probed with p-SMAD-1/5/9 and total-SMAD-1; b-Actin was used as an additional loading 
control. (D)  p-SMAD-1/5/9 protein levels were quantified by densitometry.  The signal of p-
SMAD-1/5/9 was normalized to total-SMAD-1 to control for loading variability.  Data are 
expressed as fold change relative to the media alone, which was set to 1.  Error bars represent 
one standard deviation from the mean of 3 independent biological replicates.  ANOVA, 
Dunnett’s post-hoc multiple comparisons test generated P values of:  **p < 0.01 ***p < 0.001, 
****p < 0.0001 relative to controls. This figure appears in—Bradford, S. T. J., E. J. Ranghini, 
E. Grimley, P. H. Lee and G. R. Dressler (2019). "High-throughput screens for agonists of bone 
morphogenetic protein (BMP) signaling identify potent benzoxazole compounds." J Biol Chem. 
PMID: 30602563 [50]. 
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Figure 2.2 Assessment of TGF-b effectors p-SMAD-2 and p-SMAD-3 in BRE-Luc cells.  
(A) Immunoblot of lysates from BRE-Luc cells treated with increasing concentrations of rh-
BMP4 (0, 0.4, 2, and 10 ng/ml). Membranes were probed with p-SMAD-2, p-SMAD-3, and 
total-SMAD-2/3. b-Actin was used as an additional loading control. Blot shows 3 biological 
replicates of each dose. This figure appears in—Bradford, S. T. J., E. J. Ranghini, E. Grimley, 
P. H. Lee and G. R. Dressler (2019). "High-throughput screens for agonists of bone 
morphogenetic protein (BMP) signaling identify potent benzoxazole compounds." J Biol Chem. 
PMID: 30602563 [50]. 
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Figure 2.3 High-Throughput Screening strategy in BRE-Luc cells. 
(A) A snapshot of the primary screen of 63,608 small-molecules (green dots) at a single 
concentration (10 µM) in renal BRE-Luc cells.  Positive controls were 25 ng/ml of rh-BMP4 
(red dots) whereas negative controls were 0.1% DMSO (blue dots).  The red line represents 3 
standard deviations above the DMSO.  The average luciferase induction for 25 ng/ml of rh-
BMP4 was 355,000 ± 34,000, DMSO 44,000 ± 4,300, and for the small-molecules hits 127,000.  
The average Z’ score for all the plates screened was 0.71, indicating a high-quality screening 
assay.  (B) Triage strategy used to winnow down the starting 63,608 small-molecules from the 
Primary HTS campaign which allowed identification of the top twelve BMP signaling agonists 
based on dose-response curves and structures. This figure appears in—Bradford, S. T. J., E. J. 
Ranghini, E. Grimley, P. H. Lee and G. R. Dressler (2019). "High-throughput screens for 
agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole 
compounds." J Biol Chem. PMID: 30602563 [50]. 
. 
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Figure 2.4 Dose-response curves of the top twelve potential BMP signaling agonists. 
(A) Twelve compounds were tested for BRE-Luc dose-responses at two-fold increasing 
concentrations from 0.5 nM to 10 µM in triplicate.  (B) Effective concentrations at 50% 
maximum response (EC50) and the Hill Slopes were calculated for each compound.  Maximum 
fold induction (FI) above DMSO controls is reported. (C) Chemical structures of the 12 
candidate BMP agonists are shown schematically. This figure appears in—Bradford, S. T. J., 
E. J. Ranghini, E. Grimley, P. H. Lee and G. R. Dressler (2019). "High-throughput screens for 
agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole 
compounds." J Biol Chem. PMID: 30602563 [50]. 
     
 
 69 
Materials and Methods 
 
Construction of BMP reporter cells (BRE-Luc cells)  
Human embryonic kidney cells (HEK293) were transfected with a linearized plasmid 
containing two inverted repeats of a BMP responsive element containing SMAD binding sites and 
parts of the ID1 promoter as described [48]. Transformants were selected in 800 mg/ml of geneticin 
(G418) and clones were derived by single cell dilution.  Individual BRE-Luc containing HEK-293 
clones were tested for responsiveness to BMP4 and BMP7.   
 
Cell culture   
For testing of small-molecules, BRE-Lucs were maintained in complete medium 
(Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/L D-glucose and 584 mg/L L-
glutamine supplemented with 10% fetal bovine serum and 1% Pen/Strep) and cultured to sub-
confluency at 37°C and 5% CO2.   
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Immunoblotting 
BRE-Lucs were passaged in DMEM supplemented with 5% FBS (vol/vol) for both HTS 
and 6-well plate studies. Compounds were added in the presence of 5% FBS. PRECs were serum 
starved 1hr before addition of factors in Serum Free Medium (SFM). Sub-confluent BRE-Luc or 
PREC cultures were seeded into 6-well plates at 3.0 x 105 or 2.0 x 105 cells/well respectively, using 
an automated cell counter (Countessä II). Cells were treated with rh-BMP4 (R & D Systems; 314-
BP), vehicle (DMSO-D6), or compound (10µM) for 1hr or 24hrs. After the indicated time points, 
treatment medium was removed, adhered cells were washed once in 1X PBS and subsequently 
harvested in 1X PBS and pelleted by low centrifugation.  
The cell pellet was then suspended in PK lysis buffer (50mM HEPES pH 7.5, 150mM 
NaCl, 1.5mM MgCl2, 1mM EGTA, 10% Glycerol, 1% Triton X-100, 1mM Na3VO4 50mM NaF) 
containing both phosphatase and protease inhibitors (PhosSTOP and cOmplete Mini; Roche) and 
allowed to lyse on ice for 30 minutes with intermittent vortexing. To pellet the insoluble fraction, 
the suspended pellet was centrifuged at 15,000 rpm for 15 minutes at 4°C. Supernatant was 
transferred to clean Eppendorf tubes and 6X sodium dodecyl sulfate was added 1:5 and heated for 
5 minutes at 95°C. Equal amounts of total protein lysates were resolved on hand-casted 8% SDS-
polyacrylamide gels.  
Separated proteins were then electrophoretically transferred onto Immobilonâ-FL 
polyvinylidene difluoride membranes. Membranes were dried and reactivated in methanol rinsed 
in 1X TBS and blocked for 1hr in 5% bovine serum albumin or 5% milk dissolved in 1X TBS-T 
(1X TBS + 0.1% Tweenâ 20) and then incubated overnight with primary antibodies consisting of 
one of the following: anti-Rb phospho-SMAD-1/5/9 1:1,000 (CSTâ; 13820), anti-Rb total-SMAD-
1 1:2,000 (CSTâ; 9734), anti-Rb phospho-SMAD-2 1:1000 (CSTâ; 3104), anti-Rb phospho-
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SMAD-3 1:1000 (CSTâ; 9520) anti-Rb total-SMAD-2/3 1:1000 (CSTâ; 3102), anti-b-Actin 
1:10,000 (Proteintechâ; 60008-1-Ig) The next day, membranes were washed in 1% non-fat dry 
milk prepared in 1X TBS-T and incubated for 1 hour at room temperature in anti-Rb HRP or anti-
Ms-HRP diluted in 1% non-fat dry milk (1X TBS-T). Membranes were washed in TBS-T and 
rinsed twice with 1X TBS and incubated with ECL western blotting substrate (Pierceä; 32106). 
Finally, membranes were incubated with HyBlot ESÔ autoradiography film (Denville Scientific) 
and developed on the Kodak X-OMAT 2000A processor and quantified using ImageJ (Version 
2.0.0) 
 
Small-molecule screening library  
63,608 drug/lead-like structures were screened in the Center for Chemical Genomics 
(CCG) small-molecule library housed at the Life Science Institute at the University of Michigan. 
Small-molecules were selected for their drug/lead like physicochemical properties which fell 
within the Lipinski’s space for bioavailable/orally active drugs having molecular weights < 500, 
hydrogen-bond donors < 5, hydrogen-acceptors < 10 and cLogP’s < 5 [51]. The libraries utilized 
at the CCG consisted of compounds from the ChemDiv 100K diversity set in which 61,120 
structures were screened returning a hit ratio 17.32%. 1,280 compounds from the Library of 
Pharmacologically Active Compounds (Sigma) returned a hit ratio of 9.06%.  1,280 compounds 
from the Prestwick library returned a hit ratio of 8.2% and screening 320 compounds from the NIH 
Clinical Compound library returned a 7.81% hit ratio.  
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Luciferase Assays  
Compounds were dissolved in MagniSolvÔ dimethyl sulfoxide-D6 (DMSO-D6, EMD 
Millipore; 2206-27-1) and then diluted in 5% FBS medium and added to 96-well plates. 
Recombinant proteins (rh-BMP4 or rh-Noggin, R&D Systems; 314-BP or 6057-NG) were 
reconstituted per manufactures’ instructions and diluted in 5% FBS medium. BRE-Lucs were 
passaged in 5% FBS medium and seeded into factor containing 96-well plates at 3.0 x 103 
cells/well using an automated cell counter (Countessä II). BRE-Lucs were incubated overnight at 
37°C and 5% CO2. The next day, 85% of the culture medium was aspirated using a microplate 
washer (BioTekÒ ELx405Ô) and an equal volume of luciferase reagent (Steady-GloÒ Promega) 
was added to the remaining culture medium in each well using a MultidropÔ dispenser. Following 
Steady-GloÒ cell lysis, luminescence activity was measured on a luminometer (PHEARstarÒ BMG 
Labtech) 
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 - Characterization of BMP signaling agonists identified using HTS 
 
Abstract 
 
After cell-based HTS assays are performed, multiple points along the molecular pathway 
under examination are usually interrogated as the direct molecular target is unknown. This can be 
accomplished by conducting secondary assays that measure activation of second messengers 
and/or activation of endogenous pathway genes. A plethora of other assays can also be utilized to 
help gain mechanistic insights about the “hits” identified in a cell-based HTS. Once a lead 
compound is established, structure-activity relationship (SAR) studies are also utilized to assess 
which features of the lead compound are critical to induce the observed effects of the compound. 
After screening nearly 64,000 small-molecules in a renal BRE-Luc reporter cell line we identified 
a lead compound termed sb4. We discovered that sb4 is a potent benzoxazole small-molecule that 
activates BRE-Luc in a dose-dependent manner. Furthermore, as assessed by western blotting, sb4 
was found to activate the BRE-Luc reporter by stabilizing intracellular levels of p-SMAD-1/5/9. 
The increased levels of p-SMAD-1/5/9 observed with sb4 culminate in activation of endogenous 
BMP target genes such as ID1 and ID3.  Significantly, sb4 mediated activation of the BMP 
signaling pathway is resistant to inhibition by Noggin and type I BMP receptor kinase inhibitors.  
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Introduction 
 
As discussed in Chapter 2, cell-based HTS assays provide a more physiological approach 
for screening large libraries of small-molecules compared to biochemical HTS assays, which 
employ isolated purified proteins [1]. However, with cell-based HTS the direct molecular target 
and the chemotype class that will best modulate the molecular target are both unknown [1, 2].  
Therefore, entire signaling pathways are usually the initial target of interrogation in primary cell-
based HTS assays, which as detailed in chapter 2 employ artificial reporter gene systems [1]. Being 
able to interrogate along an entire signaling pathway in cell-based HTS assays provides two 
advantages: 1) expansion of the catalog of molecular targets that can be identified and 2) 
potentially produces more diverse chemotypes for drug/lead-like identification [1].  
In secondary assays following a cell-based HTS and compound triage, endogenous 
components of the pathway can be interrogated after compound treatment to help gain mechanistic 
insights. Some secondary assays that can be used include immunoblotting for induction or 
activation of second messengers of the pathway. Or, assessing the influence of known chemical 
agents and endogenous factors of the interrogated pathway post compound treatment. 
Additionally, assessment of direct target genes in the pathway can also be evaluated after 
compound treatment. Furthermore, secondary assays also help reassure that compound treatment 
does not alter the artificial reporter gene system by unwanted mechanism [3-6].  
Using various cell types, several laboratories have identified chemical entities that 
stimulate both canonical and non-canonical BMP signaling in luciferase-based HTS. The activity 
of these chemical entities was subsequently validated and characterized further by using a variety 
of secondary assays. For instance, in a primary HTS study using mouse myoblasts (C2C12 cells) 
stably expressing a BMP response element from the ID1 promoter linked to luciferase, FK506 was 
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found to activate BMP signaling [7, 8].  For secondary assays, FK506 was tested in human 
pulmonary arterial endothelial cells in order to investigate the mechanism of action of increased 
BMP signaling observed in the primary HTS [8].  By western blotting, levels of p-SMAD-1/5/8 
were assessed after FK506 treatment for 15m, 1h, 6hrs, and 24hrs. BMP signaling as assessed by 
SMAD-1/5/8 phosphorylation, was the most robust after 15 minutes compared to the control after 
FK506 treatment. Additionally, ID1 (direct gene target of BMP signaling) levels were assessed by 
western blotting after FK506 treatment. ID1 levels after FK506 treatment were the most robust 
after 1hr of FK506 treatment.  
Additionally, FK506 was tested in LDN-193189 (type I BMP receptor inhibitor) treated 
BRE-Luc C2C12 cells and failed to induce BMP signaling [8]. Knock-down of type I BMP 
receptors (Alk1/2/3) also compromised FK506 induced BMP signaling. Moreover, 
coimmunoprecipitation studies showed that FKBP12 binds to type I BMP receptors and that 
FK506 was able to release FKB12 from Alk1, Alk2, and Alk3 [8]. Through the secondary assays 
conducted in this study, the investigators were able to conclude that FK506 activates BMP 
signaling via liberating the glycine/serine-rich domains of type I BMP receptors from FKBP12 
inhibition which allows its interaction with constitutively active type II BMP receptors such as 
BMPR2 [8].   
Alongside secondary assays, structure-activity relationship (SAR) studies are also 
undertaken as another measure to further characterize as well as optimize the hits selected after 
cell-based HTS. The idea of SAR was initially postulated more than 150 years ago and describes 
the relationship between the chemical substituents of a compound and its observed biological 
effects. Gaining SAR knowledge allows a medicinal chemist to modify the chemical substituents 
of a drug/lead-like compound to potentially achieve higher potency and/or efficacy, as well as, 
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reduce toxicity and off-target activity. To initiate SAR studies after HTS, similar compounds are 
clustered into similar groups based on common chemical motifs and expanded if needed by various 
strategies (e.g. through the purchase of analogs or medicinal chemistry efforts). Generally, 
compounds with similar structures produce similar biological effects.  However, changing a 
particular substituent could make the compound toxic or inactive, even though it may have a 
similar structure.  
SAR studies have been utilized to identify potent inhibitors of the BMP signaling pathway. 
For example, using an in vivo zebrafish assay to screen over 7,500 compounds consisting of FDA 
approved and other commercially available diverse compounds, dorsomorphin (compound C) was 
identified. Dorsomorphin was found to produce substantial and reproducible dorsalization of 
zebrafish embryos [9]. Accordingly, was the first reported small-molecule inhibitor of the BMP 
signaling pathway [9]. However, dorsomorphin had been previously recognized as an inhibitor of 
AMP-activated protein kinase (AMPK) and labeled compound C. Moreover, within the 
characterization stages of dorsomorphin, significant off-target inhibitory effects were observed on 
vascular endothelial growth factor (VEGF) type 2 receptors [10]. Therefore, in an effort to find 
analogs of dorsomorphin that did not act on type 2 VEGF receptors or AMPK, SAR studies were 
performed.  From these dorsomorphin SAR studies DMH1 (dorsomorphin homolog 1) was 
identified and found to have no activity against ALK5 (TGFbR-1), AMPK, or VEGFR2 [10]. 
Additional SAR studies have also identified LDN-193189 as potent type I BMP receptor inhibitor 
[11]. LDN-193189 is more selective than DMH1 but has activity at ALK5 and KDR [10]. Using 
SAR, LDN-212854 has also been identified as potent type I BMP receptor inhibitor [12].  
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Results: 
 
p-SMAD-1/5/9 is induced after BMP signaling agonists treatment 
Binding of BMP ligand causes heterotetramerization of type II and type I BMP receptors. 
After becoming phosphorylated by type II BMP receptors, the type I BMP receptor is activated 
and in turn rapidly phosphorylates SMADs-1/5/9—key intracellular transducers of canonical BMP 
signaling. To determine if phosphorylation of SMAD-1/5/9 was increased in the presence of our 
top twelve compounds, we treated renal BRE-Lucs for 1hr with 10 µM of each compound and 
assayed for p-SMAD-1/5/9 induction by immunoblotting. 2 ng/ml of rh-BMP4 ligand + 0.04% 
DMSO (1hr) served as our positive control and induced p-SMAD-1/5/9 10.9-fold over 0.04% 
DMSO (negative control, vehicle) (figures 3.1A-B). Additionally, we found that 1hr of treatment 
with several of our top twelve BMP signaling agonists significantly increased the abundance of p-
SMAD-1/5/9 at least 2-fold or more above the levels after 0.04% DMSO-D6 treatment (figures 
3.1A-B). That several agonists increased levels of p-SMAD-1/5/9 within 1hr ³ 2-fold, suggests 
that our BMP signaling agonists may have the capacity to directly stimulate canonical BMP 
signaling. Similarly, Genthe and colleagues recently conducted a 643,432 compound HTS assay 
which identified three compounds that stimulate canonical BMP signaling within 1hr [13].  
Collectively, this evidence supports the feasibility of identifying small-molecules using high-
throughput screening that can mimic key downstream effects of endogenous BMP ligands.  
Activation of non-canonical BMP signaling by our top twelve compounds was also 
assessed by immunoblotting for induction of mitogen-activated kinases p38, ERK1/2, and JNK.  
We found some of our BMP signaling agonists (sb7-sb11) decreased levels of p-ERK1/2 after 1hr 
of treatment but most all had little on p-p38 or p-JNK (figure 3.2A and B-C). In addition, BMPs 
stimulate the phosphorylation of transforming growth factor b-activated kinase 1 (p-TAK-1). 
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However, sb12 decreased levels of p-TAK-1, whereas there was no significant increase of p-TAK-
1 by the other compounds (figure 3.2D). To ensure specificity, we also assessed levels of the TGF-
b effectors, p-SMAD-2 and p-SMAD-3, after treatment with our top twelve BMP signaling 
agonists. Similar to rh-BMP4 dosing, the compounds had no significant effect on TGF-b signaling 
effectors. Specifically, BMP signaling agonists dosed at 10 µM for 1hr did not change basal levels 
of p-SMAD-2/3 relative to levels of p-SMAD-2/3 after 0.04% DMSO treatment (figure 3.3A).  
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BMP signaling is stimulated in renal epithelial cells after sb4 treatment  
To determine if SMAD-1/5/9 phosphorylation is induced in the presence of our top twelve 
compounds in other renal cell types, we employed serum-starved mouse primary renal epithelial 
cells (PRECs) for compound testing, which lack the BRE-Luc reporter construct. First, we assayed 
rh-BMP4 in dose-response in serum-starved PRECSs. We observed that PRECs are highly 
sensitive to rh-BMP4 treatment by detection of robust and specific p-SMAD-1/59 induction 
(figure 3.4A). After 1hr, 2 ng/ml of rh-BMP4 resulted in a 35-fold induction of p-SMAD-1/5/9 
over untreated PRECs (control) (figure 3.4B). PRECs were ~2-fold or greater more responsive to 
rh-BMP4 at each concentration tested (figure 3.4A-B) in comparison to BRE-Lucs (figure 2.1C-
D). From the top twelve BMP signaling agonists, we assayed sb4 in serum-starved PRECs. We 
observed induction of phosphorylated SMAD-1/5/9 in a dose-dependent manner (figure 3.4C-D), 
with sb4 at 100 and 300 nM yielding a 2-fold induction over 0.004% DMSO after 24hrs of 
treatment. Although not as robust as rh-BMP4, our results suggest that sb4 can significantly 
increase p-SMAD-1/5/9 abundance in PRECs under serum-starved conditions. 
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Noggin and type I BMP receptor inhibition is bypassed by sb4 
To gain insight about how our top twelve BMP signaling agonists act to induce p-SMAD-
1/5/9 and luciferase gene induction, we conducted luciferase-based inhibitor studies with both 
endogenous and chemical inhibitors of the BMP signaling pathway. Noggin is an endogenous 
inhibitor of BMP signaling that acts by sequestering dimerized BMP ligands away from BMP 
receptors and thus suppressing BMP signaling [14]. We treated cells with one of our top twelve 
BMP signaling agonists, sb4, alone or with 250 ng/ml of rh-Noggin. Our results revealed that BMP 
signaling was not suppressed when sb4 was added in the presence of Noggin (figure 3.5B). This 
is in contrast to adding rh-BMP4 in the presence of Noggin where, BMP signaling is dramatically 
suppressed (figure 3.5A). This suggests that sb4 is able to bypass negative regulation by rh-Noggin 
and activate BMP signaling. Additionally, we tested the chemical inhibitor, LDN-193189, which 
selectively inactivates type I BMP receptors [11, 15]. Sb4 remained active in the presence of 1 µM 
LDN-193189 (figure 3.5D), while rh-BMP4 activity was abolished (figure 3.5C). Taken together, 
our results indicate that sb4 works to activate BMP signaling downstream of Noggin and type I 
BMP receptors, which suggests that it works through an alternative mechanism.    
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BMP signaling efficacy is enhanced and maintained with sb4 treatment 
To determine whether the efficacy of BMP signaling is enhanced in the presence of sb4 we 
assayed varying concentrations of rh-BMP4 in the presence of a constant concentration of sb4 (10 
µM). We found that sb4 enhanced the efficacy of BMP signaling at each concentration tested of 
rh-BMP4 (0.4, 1, 10, 40 ng). The enhancing effect of sb4 was best detected when low levels of rh-
BMP4 ligand were present.  As, sb4 increased BRE-Luc expression nearly 2-fold at 0.4 and 1 
ng/ml of rh-BMP-4, the effect tapered off with higher concentrations of rh-BMP4 (figure 3.6A). 
These data show that sb4 not only activates BMP signaling independently of rh-BMP4 ligand 
(figure 3.1A-B and figure 3.4C-D) but, it also enhances BMP signaling activity. Furthermore, 
these data suggest that sb4 may act to stabilize p-SMAD-1/5/9 to enhance the transcriptional 
response.  Feng and colleagues similarly discovered that compound, PD-407824, identified in a 
4,000 compound HTS, functions as a BMP4 sensitizer in mouse C2C12 myoblasts [16].   
To test more directly if sb4 stabilizes p-SMAD-1/5/9, we examined the decay of p-SMAD-
1/5/9 after rh-BMP4 stimulation in the presence or absence of sb4. We stimulated BRE-Lucs for 
1hr with media containing 2 ng/ml rh-BMP4, removed the media, and immediately treated cells 
with either DMSO-D6 (0.004%) or 1 µM sb4 and harvested cells at 0, 5, 15, 30, 45, and 60 minutes 
after treatments. Immunoblotted lysates of cells treated with 1 µM sb4 at each timepoint had more 
levels of p-SMAD-1/5/9 than DMSO-D6 treated cells (figure 3.6B-C). In particular, cells treated 
with 1 µM sb4 for 5 minutes had significantly more p-SMAD-1/5/9 than DMSO-D6 treated cells 
after 5 minutes. This suggests that sb4 may exert its effects by protecting p-SMAD-1/5/9 from 
decay and therefore preserves BMP signaling. Cao and colleagues identified two structurally 
distinct compounds (A01 and A17) that stabilized and prolonged total-Smad-1/5 levels in both 
dose and time dependent manners, respectively, by inhibiting the interaction between total-SMAD-
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1/5 and Smurf (SMAD ubiquitination regulatory factors) which, promotes degradation of total-
SMAD-1/5 [17]. 
 
Direct BMP4 gene targets are increased following sb4 treatment  
Enhancement of BMP signaling efficacy in our luciferase and western blot studies 
prompted us to ask if endogenous direct BMP4 target genes are upregulated after sb4 dosing. Since 
our compounds mimic the activity of low-dose BMP4, we conducted a transcriptomic analysis in 
BRE-Lucs treated for 4hrs with 2ng/ml rh-BMP4. We identified thirty-one genes upregulated 
between 1.5-3.7-fold above medium only treated cells (p < 0.05) (figure 3.7A-B). We assayed two 
of the top thirty-one BMP4 target genes to determine if compound sb4 could modulate the 
expression of these genes. At 24 hrs, sb4 significantly increased the expression of ID1 and ID3 
(figure 3.7C-D). We also assayed, COL2A1, a non-significant gene in our low-dose BMP4 
transcriptomic analysis. Sb4, did not increase COL2A (figure 3.7E). 
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Analogs of sb4 increase BMP signaling in a dose-dependent manner 
Testing of structural analogs of sb4 could identify compounds with increased efficacy and 
also reveal initial structure activity relationships (SARs).  Thus, we compared 10 related 
compounds to sb4 and sb3 in our cell-based luciferase reporter assay and determined the EC50’s 
(figure 3.8).  Of these 10 compounds, 4 were inactive and 6 were active compounds with EC50’s 
ranging from 16.2 nM to 274.4 nM.  For these benzyl-thio-benzo-oxazole compounds, the 
substitution at the benzene ring of the benzyl group seems to be important.  From the initial SAR 
analysis, the data shows a very tight structure-activity relationships.  For example, benzyl or 
pyridyl for R2 makes compounds inactive as in sb4.a1 and sb4.a4 but a methyl substituted benzyl 
at the para position makes the most active compound with EC50 of 16.16 nM as in sb4.a2.  
Different substitutions of benzyl with fluorine, chlorine, and bromine at the para position as in 
sb4.a5, sb4.a3, and sb4, respectively also make compounds active but not as active as the methyl 
group.  For para substitution, methyl is the best (sb4.a2: 16.16), followed by fluorine (sb4.a5: 
60.14), bromine (sb4: 73.62), then by chlorine (sb4.a3: 77.05).  Compared to substitution at the 
para position of the benzyl as in sb4.a5, substitution at the ortho position with F as in sb3 reduces 
activity.  Compared to substitution at the para position of the benzyl as in sb4.a3, substitution at 
the meta position with Cl as in sb4.a6 makes compound 5 times less active.  Substitution at the 
ortho position of the benzyl with methoxy is 2 times less active than fluorine.  The fluorine-
substituted compound at the ortho position is 10% more active when chlorine is substituted at the 
other ortho position at the same time as in sb4.a10.  The inactivity of sb4.a7 could be either due to 
the steric effect of the substitution of methyl at the benzo-oxazole or due to the lack of aromatic 
ring at the right-hand side, or both.  The oxazolo-pyridine in place of the benzo-oxazole as in 
sb4.a9 kills the activity.  Overall, the substitutions at the para or ortho position of benzyl group is 
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preferred to at the meta position.  These data suggest that modification of benzo-oxazole is not 
tolerated. 
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Discussion 
 
 
In order to identity chemical compounds that could be the basis for developing therapeutic 
BMP signaling agonists, we designed a cell-based HTS and identified multiple specific small-
molecules that enhance and/or stabilize p-SMAD-1/5/9, key second messengers in BMP signaling.  
Our unbiased cell-based HTS identified a novel compound, sb4, that rapidly activates BMP 
signaling in renal cell cultures.  We found that sb4 increased levels of p-SMAD-1/5/9 within 1hr 
and increased the expression of direct key BMP4 target genes (ID1 and ID3).  Additionally, our 
experiments revealed that sb4 acts downstream of type I BMP receptors and bypasses negative 
regulation by Noggin, an extracellular inhibitor of BMP signaling. Moreover, in the presence of 
rh-BMP4, sb4 enhances BMP signaling efficacy by slowing the turnover or decay of p-SMAD-
1/5/9.  
Several other laboratories have also reported the identification of activators/sensitizers of 
BMP signaling in other cell types. Of note, some of these previously published BMP activators 
such as Isoliquiritigenin [18], FK506 [8], PD-407824 [16], were tested in our primary HTS screen. 
However, they did not meet our cut off for further analysis due to either having low activity in our 
primary screen or not meeting the criteria to pass our counter screen. This may underscore the 
potential of diverse compound structures to induce cell type specific responses. In a broader sense, 
it stresses the importance of identifying direct targets and determining the mechanism of action of 
these diverse compounds. As, each molecule may target different levels/aspects of canonical or 
non-canonical BMP signaling. And therefore, induce varying intensities of activation of BMP 
signaling culminating in diverse biological effects. 
Canonical receptor-SMAD-1/5/8/9 activation occurs via phosphorylation by type I BMP 
receptors.  Phosphorylation at the c-terminal transcriptional domain of SMADs-1/5/8/9 facilitates 
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co-SMAD4 docking and heteromeric SMAD transcriptional complex formation.  In addition, the 
linker interdomain of SMADs-1/5/8/9 undergo phosphorylation by cyclin dependent kinases 
(CDK8/9) and glycogen synthase 3 (GSK3), which renders R-SMADs fully functional [19]. To 
control activated BMP/SMAD-1/5/8/9 signaling duration and intensity, fundamental turnover 
mechanisms, such as dephosphorylation and ubiquitination, are necessary.  In particular, small c-
terminal domain ser/thr phosphatases (SCPs) have been identified that dephosphorylate the c-
terminal transcriptional domain of SMAD-1 after type I BMP receptor phosphorylation [20, 21] 
and the linker interdomain after CDK8/9 phosphorylation [21].  Experimental siRNA mediated 
knockdown of SCPs-1/2 conferred increased BMP signaling and Id1 expression in human 
keratinocytes and osteosarcoma cell lines [20].  Thus, small molecules such as sb4 could 
potentially inhibit such phosphatases and prove beneficial in disease states such as CKD.  
 The Smurf proteins (SMAD ubiquitination regulatory factors) also negatively regulate 
BMP/SMAD activity [22].  GSK3 phosphorylation recruits Smurfs to the BMP/SMAD linker 
interdomain to ubiquitinate activated BMP/SMADs for proteasomal degradation [23, 24].  
Increased BMP signaling is also observed following siRNA mediated knockdown of Smurf [25].  
Yes associated proteins (YAPs) are also recruited to the linker region of SMAD-1, but instead, 
function to enhance BMP/SMAD transcriptional activity and therefore signaling [25].  Because 
sb4 activates BMP signaling independent of Noggin or type I BMP receptor inhibition, it’s 
plausible that increased levels of p-SMAD-1/5/9 observed in this study can be potentially 
attributed to inhibiting SCP or Smurf activity or promotion of YAP function. Further studies are 
needed to identify the direct targets of sb4 and its analogs to unravel the precise mechanism of 
action. Future studies in particular may include screens for molecules that dephosphorylate and 
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ubiquitinate SMADs-1/5/9 in BRE-Luc cells. Once identified, later assays to determine the effect 
of sb4 on these molecules will be pertinent.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Activation of p-SMAD-1/5/9 by HTS small-molecules. 
(A) Immunoblot of whole cell protein lysates from BRE-Luc cells treated with either 2 ng/ml rh-
BMP4, 0.04% DMSO, or the top twelve BMP candidate agonists at 10 µM for 1 hour in BRE-Luc 
cells. Membranes were probed with anti-p-SMAD-1/5/9 and anti-total-SMAD-1.  b-Actin served 
as an additional loading control.  (B) Quantitation of p-SMAD-1/5/9 protein levels as determined 
by densitometry of three independently derived western blots.  The p-SMAD-1/5/9 levels were 
normalized to total-SMAD-1.  Final data are expressed as fold change relative to the mean negative 
control signal, with error bars representing one standard deviation (*p < 0.05, **p < 0.01, ****p 
< 0.0001 relative to control).  ANOVA, Dunnett’s post-hoc multiple comparisons test was used to 
determine significance.  This figure appears in—Bradford, S. T. J., E. J. Ranghini, E. Grimley, 
P. H. Lee and G. R. Dressler (2019). "High-throughput screens for agonists of bone morphogenetic 
protein (BMP) signaling identify potent benzoxazole compounds." J Biol Chem. PMID: 30602563 
[26]. 
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Figure 3.2 Evaluation of the top twelve agonists in non-canonical BMP signaling activation.  
In non-canonical BMP signaling, dimerized BMP ligands binding to their receptors can activate 
mitogen-activated kinases p38, ERK1/2, and JNK. Non-canonical BMP signaling can also activate 
p-TAK-1. Above, immunoblots of lysates from BRE-Luc cells treated with either 2 ng/ml rh-
BMP4 (positive control), 0.04% DMSO-D6 (negative control), or top twelve BMP signaling 
agonists at 10 µM for 1 hour in BRE-Luc cells. Membranes were probed with either (A) p-ERK-
1/2, b-Tubulin was used a loading control or (B) p-p38 (C) p-JNK (D) p-TAK-1, b-Actin was used 
as at loading control. This figure appears in—Bradford, S. T. J., E. J. Ranghini, E. Grimley, P. 
H. Lee and G. R. Dressler (2019). "High-throughput screens for agonists of bone morphogenetic 
protein (BMP) signaling identify potent benzoxazole compounds." J Biol Chem. PMID: 30602563 
[26]. 
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Figure 3.3 Assessment of the top twelve agonists in TGF-b signaling effector induction. 
(A) Immunoblot of lysates from BRE-Luc cells treated with either 2 ng/ml rh-BMP4 (positive 
control), 0.04% DMSO-D6 (negative control), or top twelve BMP signaling agonists at 10 µM for 
1 hour in BRE-Luc cells. Membranes were probed with p-SMAD-2, p-SMAD-3, and total-SMAD-
2/3. b-Actin was used as an additional loading control. This figure appears in—Bradford, S. T. 
J., E. J. Ranghini, E. Grimley, P. H. Lee and G. R. Dressler (2019). "High-throughput screens for 
agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole compounds." 
J Biol Chem. PMID: 30602563 [26]. 
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Figure 3.4 Activation of p-SMAD-1/5/9 by sb4 in PRECs. 
(A) Immunoblot of lysates from 1hr serum-starved PRECs subsequently treated for 1hr with 
increasing concentrations of rh-BMP4 prepared in serum free medium. (B) p-SMAD-1/5/9 
abundance, semi-quantified by densitometry. (C) Immunoblot of lysates from 1hr serum-starved 
PRECs subsequently treated for 24hrs with increasing concentrations of sb4 prepared in serum 
free medium. (D) p-SMAD-1/5/9 abundance, semi-quantified by densitometry. Membranes were 
probed with p-SMAD-1/5/9 and total-SMAD-1, b-Actin was used as an additional loading 
control.  The signal of p-SMAD-1/5/9 was normalized to total-SMAD-1 to control for loading 
variability. Final data are expressed as fold change relative to the mean negative control signal 
(0ng/ml rh-BMP4 or 0.004% DMSO-D6 which, were set to 1). Means ± SD (error bars) are 
reported. *p < 0.05, **p < 0.01 ***p < 0.001, for rh-BMP4 at 0.4ng/ml and sb4 at 0.05, 0.5, and 
1 µM p > 0.05 relative to control, 0ng/ml rh-BMP4 or 0.004% DMSO-D6  (ANOVA; Dunnett’s 
post-hoc multiple comparisons test). n = 3-4 independent biological replicates. Panels C and D 
appear in—Bradford, S. T. J., E. J. Ranghini, E. Grimley, P. H. Lee and G. R. Dressler (2019). 
"High-throughput screens for agonists of bone morphogenetic protein (BMP) signaling identify 
potent benzoxazole compounds." J Biol Chem. PMID: 30602563 [26]. 
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Figure 3.5 Effects of endogenous and chemical BMP inhibitors on sb4 activity.  
(A)  BRE-Luc cells were subjected to increasing concentrations of rh-BMP4 with (black) or 
without (red) 250 ng/ml of rh-Noggin.  Maximum concentrations of 80 ng/ml for rh-BMP4 were 
used and cells were incubated for 18hrs before measuring luminescence.  (B) A dose-response for 
sb4 was measured in BRE-Luc cells alone (blue) or in the presence of 250 ng/ml rh-Noggin 
(black).  A maximum concentration of 4 µM of sb4 was used. (C)  Activity of increasing 
concentrations of rh-BMP4 in BRE-Luc cells alone (red) or with a constant dose of 1 µM type I 
BMP receptor inhibitor (LDN-193189, black).  For both curves a maximum concentration of 1000 
pg/ml rh-BMP4 was used and cells were incubated for 18hrs before measuring luminescence.  (D) 
Increasing concentrations of sb4 were added to BRE-Luc cells alone (blue) or in the presence of 1 
µM LDN-193189 (black).  A maximum of 1000 nM of sb4 was used.  Experiments were conducted 
in triplicate. This figure appears in—Bradford, S. T. J., E. J. Ranghini, E. Grimley, P. H. Lee and 
G. R. Dressler (2019). "High-throughput screens for agonists of bone morphogenetic protein 
(BMP) signaling identify potent benzoxazole compounds." J Biol Chem. PMID: 30602563 [26]. 
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Figure 3.6 BMP signaling agonists enhance the efficacy of BMPs. 
(A) BRE-Luc cells were treated with DMSO (grey) or sb4 (blue) at a constant concentration of 10 
µM in the presence of increasing concentrations of rh-BMP4 (0.4, 1, 10 and 40 ng/ml) for 18 hours.  
Representative experiment conducted in triplicate, reported as fold change over DMSO.  (B) 
Western blot of protein lysates from BRE-Luc cells treated for 1 hour with rh-BMP4 (2 ng/ml) 
followed by fresh media containing either vehicle (DMSO) or 1 µM sb4.  Samples were harvested 
at 0, 5, 15, 30, 45, and 60 minutes after sb4 addition.  A representative western blot for p-SMAD-
1/5/9 from three independent biological experiments is shown.  (C) Ratio of p-SMAD-1/5/9 to 
total-SMAD-1 as quantified by densitometry is shown for experiments outlined in C.  Ratio of p-
SMAD-1/5/9 to total-SMAD-1 over time was compared by unpaired multiple t-tests. *p-value = 
0.02.  Note the increased stability of p-SMAD-1/5/9 in sb4 treated cells. This figure appears in—
Bradford, S. T. J., E. J. Ranghini, E. Grimley, P. H. Lee and G. R. Dressler (2019). "High-
throughput screens for agonists of bone morphogenetic protein (BMP) signaling identify potent 
benzoxazole compounds." J Biol Chem. PMID: 30602563 [26]. 
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Figure 3.7 Sb4 activates endogenous BMP4 target genes. 
(A) The top 31 genes with increased transcriptional activation after 4 hours of rh-BMP4 (2 ng/ml) 
as determined by Affymetrix microarrays.  Triplicate biological replicates were performed for 
treated and untreated groups. The p-values ≤ 0.05 and fold changes ≥ 1.5 are reported for treated 
vs. untreated groups.  (B)  Volcano plot of 6,643 genes that were measured for expression. 51 
genes were differentially expressed between treated and untreated groups.  Significant 
differentially expressed genes are shown in red dots, black and selected yellow dots represent non-
significant genes. The volcano plot was generated by uploading transcriptomic data into 
iPathwayGuide, with cut off fold change and p-values set to 0.58 and 1 respectively.  (C-E) 
Quantitative RT-PCR analysis was used to determine the relative mRNA levels of endogenous rh-
BMP4 target genes after 1 µM sb4 treatment.  The ID1 (C) and ID3 (D) genes show significant 
upregulation, whereas COL2A1 (E) remains unchanged. Data represent the mean and one standard 
deviation from three independent biological experiments performed in triplicate (**p-value < 0.01, 
ns = not significant: unpaired t-test). This figure appears in—Bradford, S. T. J., E. J. Ranghini, 
E. Grimley, P. H. Lee and G. R. Dressler (2019). "High-throughput screens for agonists of bone 
morphogenetic protein (BMP) signaling identify potent benzoxazole compounds." J Biol Chem. 
PMID: 30602563 [26].   
 
 
 
 
 
 
 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Initial Structure Activity Relationships (SAR) among 11 sb4-like compounds. 
Dose-response curves for analog structures of sb4 were tested in BRE-Luc cells.  The effective 
concentration at 50% maximum activity (EC50) was calculated and units are reported in nM for 
each structure as shown. Compounds that were not active at the concentrations tested are labeled 
NA. The PubChem ID numbers are listed below the designated name. A portion of this figure this 
figure appears in—Bradford, S. T. J., E. J. Ranghini, E. Grimley, P. H. Lee and G. R. Dressler 
(2019). "High-throughput screens for agonists of bone morphogenetic protein (BMP) signaling 
identify potent benzoxazole compounds." J Biol Chem. PMID: 30602563 [26].   
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Figure 3.9 Profile of sb4 and key mechanistic insights gained. 
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Materials and Methods  
 
Immunoblotting 
BRE-Lucs were passaged in DMEM supplemented with 5% FBS (vol/vol) for both HTS 
and 6-well plate studies. Compounds were added in the presence of 5% FBS. PRECs were serum 
starved 1hr before addition of factors in Serum Free Medium (SFM). Sub-confluent BRE-Luc or 
PREC cultures were seeded into 6-well plates at 3.0 x 105 or 2.0 x 105 cells/well respectively, using 
an automated cell counter (Countessä II). Cells were treated with rh-BMP4 (R & D Systems; 314-
BP), vehicle (DMSO-D6), or compound (10 µM) for 1hr or 24hrs. After the indicated time points, 
treatment medium was removed, adhered cells were washed once in 1X PBS and subsequently 
harvested in 1X PBS and pelleted by low centrifugation.  
The cell pellet was then suspended in PK lysis buffer (50mM HEPES pH 7.5, 150mM 
NaCl, 1.5mM MgCl2, 1mM EGTA, 10% Glycerol, 1% Triton X-100, 1mM Na3VO4 50mM NaF) 
containing both phosphatase and protease inhibitors (PhosSTOP and cOmplete Mini; Roche) and 
allowed to lyse on ice for 30 minutes with intermittent vortexing. To pellet the insoluble fraction, 
the suspended pellet was centrifuged at 15,000 rpm for 15 minutes at 4°C. Supernatant was 
transferred to clean Eppendorf tubes and 6X sodium dodecyl sulfate was added 1:5 and heated for 
5 minutes at 95°C. Equal amounts of total protein lysates were resolved on hand-casted 8% SDS-
polyacrylamide gels.  
Separated proteins were then electrophoretically transferred onto Immobilonâ-FL 
polyvinylidene difluoride membranes. Membranes were dried and reactivated in methanol rinsed 
in 1X TBS and blocked for 1hr in 5% bovine serum albumin or 5% milk dissolved in 1X TBS-T 
(1X TBS + 0.1% Tweenâ 20) and then incubated overnight with primary antibodies consisting of 
one of the following: anti-Rb phospho-SMAD-1/5/9 1:1,000 (CSTâ; 13820), anti-Rb total-SMAD-
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1 1:2,000 (CSTâ; 9734), anti-Rb phospho-SMAD-2 1:1000 (CSTâ; 3104), anti-Rb phospho-
SMAD-3 1:1000 (CSTâ; 9520) anti-Rb total-SMAD-2/3 1:1000 (CSTâ; 3102) anti-Rb-phospho-
TAK1 (CSTâ; 9339), anti-Rb-phospho-MAPK Family Sampler kit (CSTâ; 9910T), anti-b-Actin 
1:10,000 (Proteintechâ; 60008-1-Ig) The next day, membranes were washed in 1% non-fat dry 
milk prepared in 1X TBS-T and incubated for 1 hour at room temperature in anti-Rb HRP or anti-
Ms-HRP diluted in 1% non-fat dry milk (1X TBS-T). Membranes were washed in TBS-T and 
rinsed twice with 1X TBS and incubated with ECL western blotting substrate (Pierceä; 32106). 
Finally, membranes were incubated with HyBlot ESÔ autoradiography film (Denville Scientific) 
and developed on the Kodak X-OMAT 2000A processor and quantified using ImageJ (Version 
2.0.0) 
 
 
Statistical Analysis 
The following statistical test were used to assess significance and derive p-values, for each 
test, alpha = 0.05%: one-way ANOVA with post-hoc Dunnett’s multiple comparison test, unpaired 
two-tailed t-test, and multiple t-test’s (one unpaired t-test per row) by using GraphPad Prism7 
version 7.0d 
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BRE-Luc cell Transcriptome profiling 
To identify direct gene targets of low dose rh-BMP4 (2ng/ml) specifically in BRE-Lucs, cells were 
seeded at 3.0 X 105 cells in 6-well plates in triplicate for each sample. Cells were cultured in 5% 
FBS medium overnight and treated the next day with or without 2ng/ml rh-BMP4 for 4 hours. 
After treatment, BRE-Lucs were harvested to isolate total RNA using the RNeasyÒ Mini Kit 
(Qiagen) by following the manufactures’ protocol. Transcriptome profiles of low-dose rh-BMP4 
(2ng/ml) (treated) and 5% FBS medium only (untreated) cells were assessed via AffymetrixÔ 
microarray analysis performed by the Microarray Core housed within University of Michigan 
DNA Sequencing core. Concisely, the integrity and yield of total RNA was assessed by using the 
RNA 6000 Nano kit on the 2100 Bioanalyzer (Agilent Technologies). Reported RNA integrity 
numbers were above 9 for the two samples submitted in triplicate.  400ng of total RNA was used 
to generate fragmented and biotin conjugated single-stranded cDNA (ss-cDNA) using the 
GeneChipä Whole Transcript PLUS reagent kit (Applied Biosystems). ss-cDNA was then 
hybridized to the Affymetrixâ GeneAtlas Human Gene 2.1 Sense Target microarray. Following 
hybridization—wash, stain, and imaging procedures were carried out according to the 
manufactures protocol. The robust multi-array average method [27] was used to correct for 
variations between microarrays. Oligo and Limma packages of Bioconductor/R were used to 
identify differentially expressed genes by fitting normalized gene expression data to weighted 
linear models [28]. Probe sets with a variance above 0.025 and fold changes greater than 1.5 were 
selected. Multiplicity assessment was carried out by using the false discovery rate method to adjust 
p-values [29]. Final data was loaded into iPathwayGuide to generate volcano plot (Advaita 
Bioinformatics). 
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qRT-PCR 
To assess the capacity of HTS compounds to induce the expression of endogenous direct 
gene targets of BMP signaling, BRE-Lucs were seeded in 6-well plates at 3.0 x 105 cells/well and 
cultured in 5% FBS medium overnight. The following day, BRE-Lucs were treated with low dose 
rh-BMP4 (2ng/ml), 0.04% DMSO-D6, or increasing concentrations of compounds (all with 0.04% 
DMSO-D6). After 24hrs of treatment, BRE-Lucs were harvested for total RNA isolation using the 
RNeasyÒ Mini Kit (Qiagen) by following the manufactures protocol. Synthesis of first-strand 
cDNA was prepared by using 1 µg of total RNA, SuperscriptÔ III (Invitrogen) reverse 
transcriptase, and 100ng of random primers.   
Amplified cDNA templates were diluted 1:50 and SYBRÒ green Master Mix was used to 
monitor cDNA template amplification on the Applied BiosystemsÒ 7500 real-time PCR system. 
HPRT was used to normalize gene expression. For each sample, fold change of gene expression 
over 0.04% DMSO-D6 was calculated. Human primer pair sequences used were obtained from 
PrimerBank [30] (except for HPRT) and include the following:  
 
ID1-(f)-CTGCTCTACGACATGAACGG,  (r)-GAAGGTCCCTGATGTAGTCGAT 
ID3-(f)-GAGAGGCACTCAGCTTAGCC, (r)-TCCTTTTGTCGTTGGAGATGAC 
COL2A1-(f)-CCAGATGACCTTCCTACGCC, (r)-TTCAGGGCAGTGTACGTGAAC 
HPRT-(f)-ATGGACAGGACTGAACGTCTT,  (r)-TCCAGCAGGTCAGCAAAGAA 
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 - Proliferative renal diseases: Re-mining screens for Pax2 inhibitors  
 
Abstract  
 
Proliferative diseases of the kidney include polycystic kidney disease (PKD) and clear cell 
renal cell carcinoma (ccRCC). The DNA binding protein, Pax2, is implicated in the progression 
of both diseases. In the developing kidney, upregulation of Pax2 is required for the conversion of 
mesenchymal cells into epithelial cells, which upon maturation form nephrons. Once epithelial 
cells are terminally differentiated, Pax2 expression is downregulated in mature epithelial 
compartments of the nephron. In PKD, Pax2 is re-expressed and detected in the nucleus of cystic 
epithelial cells. Additionally, in the majority of ccRCCs, Pax2 is re-activated and detected in the 
diseased renal tissues. Reducing the activity of Pax2 arrests cystogenesis, as well as, decelerates 
the growth and proliferation of renal tumor cells.  
Recently, a small-molecule inhibitor of Pax2 activity, EG1, was discovered with the 
capacity to limit Pax2 mediated ureteric branching morphogenesis and aggregation of Pax2+ cells 
at ureter tip buds [1]. Additionally, EG1 limited the expression of Cited1, a Pax2 target gene  [1]. 
Following the discovery of EG1, a high-throughput screening campaign was carried out to 
discover more small-molecule inhibitors of Pax2 with different mechanisms of action [2]. The 
HTS campaign yielded 48 Pax2 inhibitors and 2 activators [2]. Most were unique structures 
precluding cluster formation needed for SAR analysis. This chapter, therefore, describes re-mining 
screens for small-molecule inhibitors of Pax2 activity, which were employed to identify a lead 
series for SAR analysis. An emerging lead series has been identified and an initial SAR analysis 
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is reported in this Chapter. These agents will require follow up studies in chromatin 
immunoprecipitation assays, kidney organoid cultures, and other assays to confirm the compounds 
in the lead series exert their effects through desirable mechanisms.   
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Introduction 
 
As discussed in Chapters 2 and 3, theoretically, cell-based HTS methods can be 
implemented to discover disease specific drugs with innovative mechanisms of action. 
Specifically, agents identified using HTS may harbor the capacity to modulate various signaling 
pathways and molecular factors implicated in a variety of diseases.  As indicated in Chapter 1, 
several unmet clinical needs exist for treating proliferative diseases of the kidney such as 
Polycystic Kidney Disease (PKD) and clear cell Renal Cell Carcinoma (ccRCC). Therefore, 
applying cell-based HTS methodologies to discover novel drug entities that can directly modulate 
molecular targets implicated in proliferative kidney diseases is warranted.  
 Many of the therapeutics currently under evaluation and in use for PKD management were 
not originally characterized for PKD treatment [3]. For instance, Tolvaptan is a highly selective 
vasopressin V2-receptor antagonist with actions in the distal portions of the nephron and it is used 
clinically for diseases associated with fluid overload [4, 5]. Under normal physiological conditions, 
arginine vasopressin, an anti-diuretic hormone, acts at vasopressin V2-receptors located in the 
distal nephrons and collecting ducts. This causes increased reabsorption of free water in the 
kidneys and stimulates increased levels of cyclic AMP [4]. Therefore, Tolvaptan under the trade 
name SamscaÒ (Japan), was originally indicated for use in hospitalized patients with dilutional 
hyponatremia (low sodium serum levels) for short-term/30-day use [6].   
Although Tolvaptan was not initially approved for cystic kidney disease, it was speculated 
early on that it might have clinical use for the treatment of diseases associated with fluid retention 
such as PKD [4]. And recently, Tolvaptan under the trade name JynarqueÒ (USA), was approved 
by the FDA for management of the autosomal dominant form of PKD. By competing for access to 
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arginine vasopressin V2-receptors, Tolvaptan, blocks binding of circulating endogenous levels of 
arginine vasopressin which results in inhibited cAMP activity.  
The vasopressin/cAMP signaling pathway is disrupted in PKD. Specifically, high levels of 
intracellular cAMP promote cystogenesis in PKD [7-9].  In both the pcy mouse model of 
nephronophthisis and the PCK rat model of the autosomal recessive form of PKD, intracellular 
levels of cAMP are significantly higher than in wild type animals [10].  Furthermore, these cystic 
animals are unable to concentrate urine and ultimately progress to renal failure [10]. Treatment of 
both pcy mice and PCK rats with the vasopressin inhibitor OPC31260 (Tolvaptan) significantly 
improved several measures of renal function and disease development including: increased kidney 
weight, plasma creatinine levels, blood urea nitrogen, renal cyst volumes, and mitotic and 
apoptotic indices [10]. Of note, pcy animals treated with OPC31260 experienced not only arrested 
disease progression but also induced disease regression [10]. Induced disease regression in pcy 
animals was indicated by the observation that the kidney weights of pcy animals undergoing 
OPC31260 therapy for 15 weeks (initiated at 15 weeks old and sacrificed at week 30) weighed 
significantly less than kidneys of untreated mice at 15 weeks of age [10].  
Even more, cystic animals with genetically ablated circulating levels of arginine 
vasopressin are protected from cyst formation and have reduced levels of cAMP.  PCK animals 
with deleted Pkhd1 crossed with animals with deleted arginine vasopressin (PCK AVP-/- animals) 
have significantly less levels of cAMP, as well as, protection against cystogenesis compared to 
PCK AVP+/+ and PCK AVP-/+ animals [11]. However, when treated with the AVP V2-receptor 
agonists, 1-deamino-8-d-arginine vasopressin (dDVAP), elevated cAMP levels return and the 
complete cystogenic phenotype is reinstated [11].  Furthermore, compared to PCK AVP+/+ and 
PCK AVP-/+ animals PCK AVP-/- animals possessed strikingly improved cysts volumes, 
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significantly lower kidney weights and volumes of fibrosis [11]. Additionally, and of note, PCK 
AVP-/- animals had enormous volumes of urine output compared to PCK AVP+/+ and PCK AVP-/+ 
animals [11].  
Although JynarqueÒ (Tolvaptan, USA) was recently FDA approved for the autosomal 
dominant form of PKD, it is only available to a subset of patients with the disease. Only patients 
with rapidly progressing autosomal dominant PKD or patients with a high risk of rapid progression 
are suitable candidates for JynarqueÒ treatment. Many factors are taken into consideration to 
determine if a patient has a rapidly progressing form of PKD. For example, young PKD patients 
with high total kidney volume and rapid PKD progression are predicted to benefit most from 
JynarqueÒ treatment [12]. Patients with a truncating PKD1 mutation are also expected to benefit 
from JynarqueÒ treatment due to its association with rapid disease progression [12].  
While rare, a serious adverse side effect of JynarqueÒ treatment is hepatotoxicity which 
may necessitate liver transplantation if left unchecked. Accordingly, frequent tests to monitor liver 
function are required for all patients on JynarqueÒ  in order to continue therapy. 
JynarqueÒ treatment must be discontinued if elevated liver enzymes fail to return to acceptable 
levels. More common side effects of JynarqueÒ treatment include frequent urination and intense 
thirst. JynarqueÒ treatment induces high sodium serum levels; therefore, patients must drink 
several liters of water per day in order to prevent severe dehydration. To reach more patients and 
reduce the chance of severe side effects, alternative therapeutic strategies are needed for safe and 
effective long-term treatment of both the autosomal recessive and dominant forms of PKD. 
The transcription factor, Pax2, has been implicated in the progression of proliferative 
kidney diseases and is an emerging target for small-molecule inhibition. In renal epithelial cells 
(MDCKs) Pax2 has been shown to be repressed by the commonly mutated PKD gene Pkd1 which 
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encodes Polycystin-1 [13]. Specifically, in overexpressing Pkd1 renal epithelial cells, Pax2 protein 
levels and promoter activity are significantly repressed relative to control cells lacking the Pkd1 
transgene [13]. In normal developing kidneys, Pax2 is required for mesenchymal-to-epithelial cell 
conversion and Pax2 expression is classically detected in emerging nephrons [14, 15]. Mature 
nephrons, however, terminate Pax2 expression prior to completing the epithelial differentiation 
program [13, 15, 16]. In mice mimicking the recessive form of PKD, cpk and the autosomal 
dominant form of PKD, Pkd1del34/del34, Pax2 is re-expressed and detected in the nucleus of cystic 
epithelial cells [13, 17]. Importantly, transgenic overexpressing Pax2 animals develop microcysts 
in the glomerulus and proximal tubules [16]. Similar to the vasopressin deficient cystic animals 
(PCK AVP-/-) described above, cpk and Pkd1del34/del34 cystic animals with reduced Pax2 dosage 
have arrested cystogenesis [13, 17]. Moreover, there is a marked reduction in the weight of kidneys 
from cpk and Pkd1del34/del34 animals heterozygous for Pax2 relative to the weight of kidneys from 
cystic animals homozygous for Pax2 [13, 17]. Inhibiting Pax2 activity arrests cystogenesis in these 
animals and decreases total kidney weight. Therefore, inhibiting Pax2 activity with small-molecule 
inhibitors may also slow the growth of cysts in both autosomal recessive and dominate PKD. 
Clear cell renal cell carcinoma (ccRCC) like polycystic kidney disease is another 
proliferative kidney disease that ultimately progresses toward end-stage renal failure.  Unlike 
polycystic kidney disease which has only one FDA approved therapy, several targeted FDA 
therapies with different mechanisms of action exist for managing ccRCC. The development of 
resistance to these therapies, however, hinders effective long-term treatment of ccRCC. Lesions in 
the VHL gene are suggested to occur in 90% of ccRCC cases through genetic or epigenetic 
mechanisms [18].  Under normal physiological conditions, VHL regulates HIF-1a activity. 
Consequently, in ccRCC, VHL lesions lead to constitutively active HIF-1a and the pathological 
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activation of HIF-1a target genes. HIF-1a target genes such as vascular endothelial growth factor 
(VEGF) and mechanistic target of rapamycin (mTOR) are important mediators that drive 
malignant tumor behavior.  
With early detection, partial or total nephrectomy can be implemented to treat ccRCC. 
Commonly, however, ccRCC progresses without noticeable symptoms which can result in 
metastasis and 30% of nephrectomy patients will develop metastatic spread of ccRCC [19, 20].  
First- and second-line targeted treatments, therefore, are employed for the treatment of metastatic 
ccRCC. First-line targeted therapies for metastatic ccRCC include small-molecules Sorafenib and 
Sunitinib which inhibit VEGF receptor tyrosine kinases. Sorafenib and Sunitinib have activity on 
other tyrosine kinases such as PDGFRB (platelet-derived growth factor receptor b),  Flt-3 (FMS-
like tyrosine kinase), c-Kit (receptor of stem cell factor), and RET receptor tyrosine kinases [21]. 
Sorafenib and Sunitinib primarily exert their effects through inhibition of tumor angiogenesis and 
proliferation [21, 22]. The average duration of clinical control of ccRCC under first-line 
therapeutics is 8-9 months [19]. Side effects of both Sorafenib and Sunitinib include: hypertension, 
diarrhea, hand-foot syndrome, rash, and mucositis [19].  
In patients with metastatic ccRCC that have experienced disease progression on first-line 
VEGF receptor inhibitors, second-line targeted therapies for metastatic ccRCC are implemented. 
Second-line targeted therapies for metastatic ccRCC include Everolimus and Temsirolimus which 
inhibit the serine-threonine kinase mTOR, a central regulator of cell growth [23]. Everolimus and 
Temsirolimus bind to FKBP-12 and form an inhibitory complex that inactivates mTOR signaling 
[24, 25]. Everolimus and Temsirolimus inhibitory actions on mTOR result in a decrease in proteins 
that regulate cell cycle progression and angiogenesis [24]. The average duration of controlling 
ccRCC under second-line therapeutics is 5-6 months [19]. Side effects of both Everolimus and 
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Temsirolimus include: stomatitis, hypercholesterolemia, hyperglycemia, pneumonitis, and edema 
[19].  
In developing renal tissues, Pax2, is essential for specifying and restricting the fates of 
renal stem cells [15]. Pax2, therefore, is activated in the renal mesenchyme and proliferating renal 
epithelial cells [15].  Once terminally differentiated, however, mature renal epithelial cells silence 
Pax2 activity. Conversely, in the majority of ccRCC, Pax2 is re-activated and detected in the 
malignant renal epithelium [26]. As detailed above, mutated VHL is unable to negatively regulate 
HIF-1a, causing pathogenic activation of a number of HIF-1a target genes. And, along with the 
negative regulation of HIF-1a, VHL also suppresses Pax2; as, loss of VHL induces Pax2 up-
regulation in ccRCC [27]. In addition, a correlation between HIF-1a and Pax2 in ccRCC has been 
identified in patient tumors [27]. Furthermore, it has been suggested that prolonged activation of 
Pax2 may restrict the differentiation potential of renal epithelial cells [16]. Downregulation of 
Pax2 activity, however, by antisense oligonucleotides decelerates the growth and proliferation of 
renal tumor cells [28].  Moreover, downregulated Pax2 enhances cisplatin-induced apoptosis in 
renal carcinoma cells and RCC derived xenographs with ablated Pax2 (shPax2) [29, 30].  
Therefore, inhibiting Pax2 activity with small-molecule inhibitors may also slow the growth and 
proliferation of renal carcinoma cells alone or in combination with other currently approved 
targeted therapeutics. 
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Results 
 
To identify small-molecule inhibitors of Pax2 that could potentially be developed to slow 
the progression of polycystic kidney disease (PKD) and clear-cell renal cell carcinoma (ccRCC) 
we designed a cell-based HTS assay that allowed initial screening of 69,125 chemical compounds, 
which was carried out by Grimley [2]. After applying triage criteria, Grimley tested 233 inhibitors 
and 110 activators of Pax2 in dose-response [2]. This was followed by fresh powder stock retesting 
of 146 confirmed inhibitors and 8 confirmed activators in dose-response [2]. After running 
counterscreening assays, Grimley found a total of 50 “hits” that remained promising candidates 
for modulating Pax2 activity [2]. 48 were inhibitors and 2 were activators of Pax2 activity [2].   
 Many of the top 50 “hits” displayed favorable dose-response activity with some having 
single digit micromolar IC50’s, selection of a lead series for SAR analysis, however, was stalled. 
This was because most of the compounds were singletons/unique structures (at least 37 structures 
were unique) [2]. Grimley, however, did report one cluster with 7 members and 2 clusters with 2 
members [2]. To expand the on the 50 “hits” found by Grimley, we initiated re-mining screens in 
order to identify molecules with similar structures to the 50 “hits” identify by Grimley that had not 
been tested in the initial small-molecule screening assays. Overall, we wanted to improve our 
prospects of identifying the best chemical series with satisfactory SAR for Pax2 inhibition.  
 We performed a similarity search of the entire Center for Chemical Genomics (CCG) 
screenable library using the 50 “hits” as queries with structure similarity set to 75%. From this 
search criteria, we identified over 300 compounds that had not been previously screened in our 
initial assays. We performed dose-response assays using 8-point titration curves generated with a 
1.67 dilution factor in renal cells containing an integrated Pax Response Sequence (PRS4-Luc 
cells). The titration curves had a top concentration of 50 µM and a final concentration of 1.38 µM. 
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PRS4-Luc reporter cells were transiently transfected with a Pax2 expression construct and treated 
with either DMSO or compounds using the titration curve described above. 122 compounds out of 
373 compounds in our re-mining screen were active in the concentration response curve (CRC) 
assays (hit rate of 33%). 
Cluster analysis was performed on 122 active compounds using DataWarrior software [31]. 
47 clusters were identified with 80% similarity and 34 clusters were identified with 70% similarity. 
17 clusters were eliminated based on reactive filters flags, range of activities within the cluster, 
chemical structures, etc. The most active compound was selected from each of the 17 remaining 
clusters to purchase fresh powder. 15 compounds were available for purchase through our selected 
vendor. The activities in CRC for compounds from the fresh powder confirmed the original CRC 
activities even though activities were slightly higher from fresh powder than the original for most 
of the compounds (table 4.1).  
Since the original CRC activities were confirmed by the fresh powder, we went back to 
perform an initial SAR for the original 122 CRC active compounds. From the 34 clusters, one 
series of compounds are beginning to clearly emerge in terms of the number of compounds in the 
cluster, the range of activities, and compounds with related structures to the other clusters (figure 
4.2). There are 23 compounds in this particular cluster, and they were combined with 12 
compounds from other clusters since they had related structures. A set of 35 compounds in total 
was tabulated for an initial SAR analysis. The activities (pAC50) range from 3.8 – 5.48. The IC50 
values are also reported in Table 4.2. The CRC activities of the original CCG powder and the fresh 
powder for 6 compounds in this set were compared in Table 4.1.   
The initial SAR analysis and the R group analysis are in Table 4.2. In this set of 35 
compounds, there are five compounds with quinazoline cores. The open chain as R2 is more active 
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than the cyclized group. The methyl substitution of the benzene ring of R1 decreases the activity. 
There are 21 compounds with a piperazine core showing an excellent initial SAR. In this series, 
[1,2,4]triazolo[1,5-a]pyrimidine group is prevalent as either R1 or R2, 5 compounds have it as R1 
and 6 compounds have it as R2. Also, the structurally related group, 5,6,7,8-tetrahydro-
[1,2,4]triazolo[5,1-b]quinazoline is in 4 compounds as R1 and in 6 compounds as R2. The most 
active compound has [1,2,4]triazolo[1,5-a]pyrimidine group as R1 and a di-methyl substituted 
benzene at the ortho and meta positions. For the same R2, having [1,2,4]triazolo[1,5-a]pyrimidine 
as R1 makes the compound more active than  5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazoline. 
. 
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Discussion 
 
Although Pax2 is an established target in proliferative disease of the kidney, currently, 
there is a dearth of chemical agents/tools available to modulate this molecule proved to be critical 
in both kidney development and disease.  In silico/virtual screening methodologies combined with 
the use of a homology model of the Pax2 paired domain, led to the discovery of the first ever 
reported small-molecule inhibitor of Pax2, EG1, by Grimley and colleagues [1].  In the study by 
Grimley and colleagues, renal carcinoma cell lines harboring re-activated Pax2 expression 
exhibited decreased viability and proliferation following EG1 treatment. Moreover, cultured 
embryonic kidney rudiments treated with EG1 displayed defects in Pax2 mediated ureteric 
branching morphogenesis and incomplete aggregation of Pax2+ cells at ureter tip buds [1].  
As discussed in Chapters 2 and 3, cell-based high-throughput screening methodologies 
provides investigators with an unbiased means to discover drug entities that can potentially 
modulate disease targets. As well as, a method to discover drugs with novel mechanisms of action. 
Therefore, using high-throughput screening methodologies, Grimley was able to identify at least 
50 more small-molecules with the capacity to modulate Pax2 transcription activation [2]. This 
Chapter discuses re-mining efforts to find compounds with similar structures to the 50 small-
molecules identified by Grimley.  
Collectively, the aim of these studies is to discover molecules that have the capacity to not 
only inhibit Pax2-DNA-binding interactions but that also have the capacity to inhibit the formation 
of complexes between Pax2 and its binding partners, i.e., protein-protein interactions (PPIs). For 
example, the Pax transactivation domain interacting protein (PTIP) interacts with the carboxy-
terminal transactivation domain of Pax2 [32]. The Pax2 and PTIP complex co-localize to sites of 
actively expressed chromatin in the cell nucleus [32]. PTIP then recruits and links the MLL3/4 
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histone H3K4 methyltransferase complex to Pax2 [33]. Whereby, the Pax2-PTIP-MLL complex 
is able to imprint and maintain active epigenetic marks on chromatin [15].  Some Pax2 binding 
partners act in a repressive manner to inhibit Pax2 transactivation activity and thus silence the 
genome. For instance, the groucho-related gene 4 (Grg4) is a binding partner of Pax proteins [34, 
35].  Grg4 inhibits Pax protein transcriptional activity in an octapeptide dependent manner to 
permit silencing of specific genes [34, 35]. Hence, inhibiting the ability of Pax2 to interact with 
proteins such as PTIP or enhancing interactions between Pax2 and Grg4 may provide additional 
therapeutic strategies to arrest cystogenesis in PKD and decelerate ccRCC. Furthermore, agents 
that work by modulating Pax2 protein-protein interactions could potentially improve the ability to 
potently control tissue specific protein-protein interactions with precision and efficacy. By 
comparing such compounds to the activity of EG1 we can assess the extent of Pax2 inhibition.   
Ectopic expression or re-activation of Pax2 is implicated in the progression of both PKD 
and ccRCC.  Therefore, efforts to identify agents that have the capacity to modulate Pax2 activity 
by novel mechanisms is warranted.  Currently, JynarqueÒ (Tolvaptan, USA) is only FDA approved 
treatment for the autosomal dominant form of PKD and is only accessible to a sub-group of PKD 
patients. On the other hand, several approved FDA therapies exist for ccRCC management (e.g. 
Sorafenib, Sunitinib, Everolimus, and Temsirolimus). However, the development of resistance to 
inhibitor drug therapy is a huge barrier which prevents effective long-term treatment. Available in 
vitro systems and in vivo models of both PDK and ccRCC will aid the process of validating the 
efficacy of potential novel small-molecule modulators of Pax2 transactivation activity.  
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Figures 
  
 
Figure 4.1 Re-mining strategy to test additional small-molecules in PRS4-Luc cells. 
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Table 4.1 Comparison of CRC activities between original and fresh powder compounds 
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Figure 4.2 Fresh powder dose-response curves of emerging lead series of Pax2 inhibitors. 
Using fresh powder isolates, we performed dose-response assays using 8-point titration curves 
generated with a 1.67 dilution factor in renal cells containing an integrated Pax Response Sequence 
(PRS4-Luc cells).The titration curves had a top concentration of 50 µM and a final concentration 
of 1.38 µM. (open squares): DMSO/D6 was tested in a counter-cell line which lacks PRS4-Luc.  
The hypothesis was that DMSO would have no effect in the counter cell line and accordingly, 
these experimental conditions were used as a control. (filled squares): DMSO/D6 was tested in 
PRS4-Luc cells transiently transfected with a Pax2 expression construct. The hypothesis was that 
DMSO/D6 would have no effect on Pax2 transactivation activity. (open circle): Assessment of 
compound activity in the counter-cell line which lacks PRS4-Luc. The hypothesis was that Pax2 
inhibitors would have no activity in the counter cell line. Suitably, these conditions were used to 
screen for non-specific activity of Pax2 inhibitors. (filled circle/red curve): Pax2 actives tested in 
PRS4-Luc cells transiently transfected with Pax2. The hypothesis is that Pax2 actives would have 
an inhibitory effect on Pax2 transactivation activity. (filled star): Baseline activity of PRS4-Luc 
cells without transfected Pax2. The hypothesis was that identified Pax2 inhibitors would produce 
a curve similar to cells lacking transfected Pax2. Thus, these conditions were used as a positive 
control. Note the range of inhibitory activities in the compounds within the emerging lead series 
of Pax2 inhibitors (red curves). 
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Table 4.2 Initial SAR analysis of a set of 35 CRC active compounds 
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sbeg-13/
191865
124738832 4.58 2.63E-05 26.30
sbeg-14/
191876
124738843 4.45 3.55E-05 35.48
sbeg-15/
191879
124738846 4.68 2.09E-05 20.89
sbeg-16/
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124738847 3.94 0.000115 114.82
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sbeg-25/
191952
124738919 4.55 2.82E-05 28.18
sbeg-26/
191955
124738922 4.46 3.47E-05 34.67
sbeg-27/
191086
124738111 3.8 0.000158 158.49
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191087
124738112 5.38 4.17E-06 4.17
sbeg-28/
191866
124738833 4.26 5.5E-05 54.95
sbeg-29/
191872
124738839 4.19 6.46E-05 64.57
sbeg-30/
191874
124738841 4.24 5.75E-05 57.54
sbeg-31/
191884
124738851 4.08 8.32E-05 83.18
sbeg-32/
191091
124738116 4.34 4.57E-05 45.71
sbeg-33/
190303
124737434 4.46 3.47E-05 34.67
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124738879 4.47 3.39E-05 33.88
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Materials and Methods 
 
Cell-Culture 
For testing of small-molecules, HEK293 cells carrying an integrated Pax Response 
Sequence driving luciferase (PRS4-Luc) were maintained in complete medium (Dulbecco’s 
modified Eagle’s medium (DMEM) containing 4.5 g/L D-glucose and 584 mg/L L-glutamine 
supplemented with 10% fetal bovine serum and 1% Pen/Strep) and cultured to sub-confluency at 
37°C and 5% CO2.   
 
Transfection Procedure 
 As described previously [1], PRS4-Luc cells were seeded into CorningÒ 100 mm tissue 
culture-treated culture dishes at 3.0 x 106 and grown overnight. The following morning, PRS4-Luc 
cells were approximately 50% confluent and media exchange was performed with 5 mls of fresh 
complete media lacking 1% Pen/Strep. PRS4-Luc cells were then transiently transfected with or 
without CMV-Pax2b. The transfection plasmid DNA-lipid complex consisted of: 4 µg of CMV-
Pax2b plasmid DNA (4 µL obtained from 1 µg/µl plasmid DNA stock) combined with 910 µL of 
Opti-MEMä I (Gibcoä) for a total of 914 µL, as well as, 14 µL of Lipofectamine 2000Ò reagent 
(Life Technologiesä) and 900 µL of Opti-MEMä I (Gibcoä) for a total of 914 µL. The 
transfection plasmid DNA-lipid complex reagent was mixed and allowed to incubate for 20 
minutes at room temperature. The plasmid DNA-lipid complex consisting of 1828 µL was then 
added dropwise to the overnight cultured PRS4-Luc cells described above. The PRS4-Luc cells 
containing the transfection reaction was then allowed to incubate for 6 hours at 37°C and 5% CO2. 
Transfection reaction plates were gently shaken at 30 mins and 60 mins post-transfection.  
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Luciferase Assays 
 PRS4-Luc cells transfected with CMV-Pax2b were trypsinized and counted using an 
automated cell counter (Countessä II). 6 x 103 cells/well were then seeded into 384-well plates 
containing small-molecules using complete medium. Under 37°C and 5% CO2 conditions, PRS4-
Lucs were incubated overnight with the small-molecules for the re-mine screen. The next day, 
culture medium was aspirated using a microplate washer (BioTekÒ ELx405Ô) so that 10 µL 
remained and an equal volume of luciferase reagent (Steady-GloÒ Promega) was added to the 
remaining culture medium in each well using a MultidropÔ dispenser. Following Steady-GloÒ 
cell lysis, luminescence activity was measured on a luminometer (PHEARstarÒ BMG Labtech). 
 
Small-molecule screening library utilized for re-mining efforts  
Over 300 drug/lead-like structures were screened from the Center for Chemical Genomics 
(CCG) small-molecule library housed at the Life Science Institute at the University of Michigan. 
Small-molecules were selected for their drug/lead like physicochemical properties which fell 
within the Lipinski’s space for bioavailable/orally active drugs having molecular weights < 500, 
hydrogen-bond donors < 5, hydrogen-acceptors < 10 and cLogP’s < 5 [36]. Compounds utilized 
for re-mining efforts were sourced from the ChemDiv 20K collection (65 active compounds), 
ChemDiv 100K collection (53 active compounds), NCI collection (1 active compound), MB_24K 
collection (2 active compounds) and the CMLD collection (1 active compound) which are all 
housed in the CCG library.   
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Fresh-powder sources for confirmation dose-response studies 
The sources of the fresh powder compounds use for dose-response confirmation studies 
were obtained from Aldrich Market Select which contains 8 million searchable unique structures. 
Purity of compounds ranged from 90-92%, and they were synthesized by AMS suppliers 
including: Princeton BioMolecular Research (1 compound), Vitas-M Laboratory, Ltd. (7 
compounds), InterBioScreen Ltd. (1 compound), and ChemDiv, Inc (6 compounds). 
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 - Conclusion and Future Directions 
TGF-b and BMP signaling are implicated in the progression and reversal of CKD 
 
Patients with Chronic Kidney Disease whether of the fibrotic or proliferative subtypes have 
limited therapeutic options once end-stage kidney disease is reached. Chronic kidney dialysis or 
kidney transplantation are the only therapies available. Chronic kidney dialysis is costly and does 
not restore full kidney function, while donor kidneys for transplantation are a scarce medical 
resource. Therefore, alternative strategies to treat kidney diseases are desperately needed. Several 
targets implicated in the progression or reversal of CKD (kidney fibrosis or proliferative kidney 
diseases) can be targeted for treatment. As demonstrated in this dissertation, high-throughput 
screening technologies can be applied towards the identification of drug/lead-like molecules that 
can potentially modulate signaling pathways and targets involved in kidney disease.  
Longstanding studies have underscored persistent TGF-b activity as the principle driver of 
fibrogenesis in the kidney. TGF-b is a signaling cytokine and growth factor that helps orchestrate 
organ development, as well as, tissue repair and regeneration.  However, overexpression or 
exogenous administration of TGF-b leads to the development of fibrotic lesions in the kidney and 
other organs. For instance, transgenic animals expressing high levels of TGF-b1 selectively in 
hepatocytes develop liver fibrosis [1]. In addition, although these animals selectively express TGF-
b1 in hepatocytes, they also exhibit high circulating levels of TGF-b1, which leads to the 
development of chronic glomerulonephritis [1] and progressive glomerulosclerosis [2].  
Exogenous administration of TGF-b2 in animals leads to the development of renal fibrosis  
[3]. Similarly, in an eleven participant phase I clinical study of systemic administration of TGF-
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b2 to multiple sclerosis patients, three participants experienced a decline in GFR of  > 25% of the 
baseline value [4]. Notably, two participants from this clinical study developed hypertension under 
TGF-b2 trial therapy [4]. Hypertension is the second leading cause of end-stage renal disease and 
TGF-b1 has also been reported to be overexpressed in hypertensive patients compared to 
normotensive controls [5]. Even more, TGF-b1 is hyperexpressed in hypertensive patients that are 
Americans of African descent compared to Americans of European descent [5].  
In animal models of kidney disease, neutralizing TGF-b activity reduces renal damage 
caused by excessive TGF-b activity. For example, anti-TGF-b1 treatment administered at the 
same time as the induction of glomerulonephritis causes evident suppression of extracellular 
matrix accumulation and fibrotic lesions [6]. On the other hand, genetic ablation of TGF-b in 
animals leads to uncontrolled inflammation and animal death within a couple of weeks [7, 8].  
These observations underscore the benefits of suppressing TGF-b in renal disease, however, 
suppression or excessive suppression of TGF-b could lead to inflammatory lesions and other 
unwanted side effects. The mechanisms regulating elevated and prolonged TGF-b activity in 
chronic kidney disease are unclear. However, pathological levels of TGF-b could be activated in 
renal fibrosis by a plethora of aberrant mechanisms ranging from overactive integrin-ab receptors 
to suppression of negative regulators of TGF-b.  
Therefore, numerous drug discovery programs for the treatment of chronic kidney disease 
have been designed around suppressing the pathological activity TGF-b. For example, a 
humanized monoclonal TGF-b1 anti-body was developed by Eli Lilly and Company and tested 
for efficacy in diabetic nephropathy patients under renin-angiotensin system inhibitor therapy [9]. 
This clinical trial, however, was terminated early due to a lack of efficacy (no change in baseline 
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serum creatinine). Several explanations were proposed for the lack of efficacy including:  1) 
inadequate enrollment of American patients of African descent and type I diabetic patients 2) 
serum creatinine as a final efficacy marker was not sensitive enough to detect a beneficial effect 
3) potentially higher doses of TGF-b or more frequent administration were needed.  However, lack 
of success from this clinical trial may also suggest that in order to achieve a long term and full 
therapeutic effect other key pathways involved in the reversal of chronic kidney disease may need 
to be activated in combination with safe TGF-b suppression, i.e. avoiding excessive suppression 
which may be systemically toxic. 
In contrast to work establishing TGF-b as the principle driver of renal fibrogenesis, seminal 
studies conducted over two decades ago were the first to provide evidence of renoprotection by 
BMPs. BMPs are a major branch of the TGF-b superfamily of signaling cytokines and growth 
factors. BMPs have important roles in the development, homeostasis, and disease processes of an 
array of tissue types. Particularly, BMPs are critical in the development of healthy kidneys [10]. 
In animal models of renal disease/fibrosis, however, BMP signaling is suppressed and 
reestablishment of BMP signaling reverses renal injury [11-16]. The direct molecular mechanisms 
underlying the beneficial actions of BMPs in the fibrotic kidney, however, remain elusive [17, 18]. 
Although, it is speculated that BMPs reactivate similar programs that it uses during kidney 
development to also repair injured renal tissues [14].  
As there are many mechanisms that can activate TGF-b signaling in fibrotic kidneys, there 
are several ways in which BMP signaling can become dysregulated in fibrotic kidneys. For 
example, negative regulators of BMP signaling such as USAG-1, Gremlin, and CTGF may be 
aberrantly expressed in fibrotic kidneys [19-21]. Interestingly, in contrast to animal models with 
suppressed BMP signaling, early stage kidney disease patients with proteinuria have elevated 
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levels of BMP expression [22] along with elevated levels of the negative regulators of BMP 
signaling Gremlin [23, 24] and Connective Tissue Growth Factor (CTGF) [25]. Certain 
pathological conditions may cause low BMP receptor expression, which is another dynamic to 
consider that may contribute to dysregulated BMP signaling [17, 26]. 
Pre-clinical animal studies conducted to test the efficacy of THR-123, a cyclized peptide 
agonist of the type I BMP receptor, Alk3, demonstrated the ability to reverse established kidney 
fibrosis [27]. The investigators conducting this study reported that THR-123 reversed kidney 
fibrosis by suppressing inflammation, apoptosis, and epithelial-to-mesenchymal transition even 
though Alk3 receptors were depleted during end-stage kidney disease [27]. However, similar to 
the clinical trial assessing the efficacy of anti-TGF-b therapy in patients with diabetic nephropathy 
[9], perioperative use of THR-184 (THR-123 analog) in patients with cardiac surgery induced 
acute kidney injury yielded futile results [28]. THR-184 did not reduce the incidence of acute 
kidney injury within seven days of cardiac surgery [28].  Lack of efficacy of THR-184 was 
attributed to an insufficient dosing strategy which included inadequate administration of the 
frequency and duration of THR-184 [28].  
Lack of efficacy of THR-184 in patients with cardiac surgery may also suggest the need 
for combination treatments. Ideally, combination treatments would work to safely repress 
pathological levels of TGF-b activity and simultaneously activate repressed BMP signaling which 
are detected in chronic kidney disease. To improve effectiveness further, these combination 
treatments would also ideally possess mechanisms that bypass negative regulators of BMP 
signaling such as Gremlin as well as act independently of BMP receptor status.   Overall, it would 
be important clinically to reduce destructive ECM deposition driven by TGF-b and promote 
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regeneration of damage cellular constituents of the kidney, which are suggested to be encouraged 
by BMP signaling.  
Future investigations to further develop the identified BMP signaling agonists  
 
The first aim of the work described in this dissertation was to identify small-molecules that 
activate the BMP signaling pathway. Using HTS methods, several small-molecules were identified 
that activated a BRE-Luc reporter construct in a dose-dependent manner. Half maximal effective 
concentrations were calculated and ranged from approximately 74 nM to 1249 nM. In the presence 
of some of these small-molecule BMP signaling agonists, levels of p-SMAD-1/5/9 were 
significantly increased. For instance, after treatment with the BMP signaling agonists, sb4, levels 
of p-SMAD-1/5/9 were significantly increased 2.61-fold over baseline levels of p-SMAD-1/5/9 in 
DMSO treated samples. This finding and the fact that sb4 had the lowest EC50 prompted selection 
of sb4 as the first of the top twelve BMP signaling agonists to be interrogated further in mechanistic 
assays.  
Notably, after treatment with the other BMP signaling agonists such as sb7 (EC50 = 118.2 
nM) and sb8 (EC50 = 129.1) levels of p-SMAD-1/5/9 were also significantly increased by 3.15- 
and 2.96-fold respectively. Significantly increased levels of p-SMAD-1/5/9 were also detected 
after treatment with sb5 (EC50 = 549.5 nM) and sb6 (EC50 = 983.2 nM) by 3.13- and 3.73-fold 
respectively over DMSO treated samples. Given these findings, it is important to conduct follow-
up studies with these additional BMP signaling agonists to determine if they act in a similar or 
different manner in comparison to sb4. For example, sb4 was shown to have modest effects on the 
endogenous BMP target genes ID1 and ID3. However, it is possible that some of the other BMP 
signaling agonists identified might increase the magnitude of activation of BMP target genes 
beyond what as detected with sb4. Although, it is important to consider that the modest effects of 
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sb4 may be advantageous because they may produce less side effects than rh-BMPs, which are 
very potent under optimal conditions. This could also be a beneficial feature of a drug that needs 
to be used long term in chronic diseases such as CKD.  
Expansion of the initial/catalog-based SAR studies conducted on sb4 will also be 
necessary. Although the initial SAR highlighted that substitution at benzene ring for R2 is 
important for the activity of sb4 and sb4-like compounds, the SAR data was very tight (narrow 
SAR). In order to conduct a more in-depth SAR analysis, sb4 will first need to be resynthesized 
(to ensure sb4 is still active and has the same potency in assays utilized) and many more 
compounds with similar structures to sb4 will need to be tested to better assess the relationship 
between structure and activity.  
The procedure outlined above will also be necessary to conduct for the additional BMP 
signaling agonists identified that have promising activities such as compounds sb5, sb6, sb7, and 
sb8. It will be ideal to first determine if after treatment with these compounds endogenous BMP 
signaling target genes are increased. Once this is established, these small-molecules should also 
be resynthesized and tested alongside compounds with similar structures to aid in-depth SAR 
analysis. It is possible that testing structures with similar structures to sb5, sb6, sb7, and sb8 might 
yield even more potent and/or efficacious compounds. Furthermore, information gained from these 
future SAR studies could also aid in the development of assays to determine the direct binding 
target(s) of these BMP signaling agonists.  
As mentioned above, sb4 was selected as the first of the top twelve BMP signaling agonists 
to be studied in further detail.  Work conducted in this dissertation found that sb4 stimulates BMP 
signaling by stabilizing p-SMAD-1/5/9. The increased levels of p-SMAD-1/5/9 therefore resulted 
in increased expression of direct BMP targets genes, ID1 and ID3.  Work from this dissertation 
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also found that sb4 is resistance to both Noggin and type I BMP receptor inhibition. The 
mechanism of BMP signaling activation such as that demonstrated by sb4, which bypasses 
negative regulation by Noggin and potentially similar negative regulators of BMP signaling, could 
be beneficial in specific clinical situations where these negative regulators are elevated. Further, 
the ability to activate BMP signaling when type I BMP receptors are inhibited could also be a 
useful mechanism in the event receptor status is low due to diseased states [17, 26, 27]. Moreover, 
compounds like sb4 could synergize with endogenous levels of BMPs and potentially abrogate the 
need for harmful doses of exogenous BMPs that lead to unwanted side effects [29-31]. 
Compounds with a benzoxazole moiety similar to sb4, have been reported to have 
important clinical applications. Pharmacological activities include working as anti-inflammatory 
[32] and anti-diabetic agents [33]. Studies in this dissertation suggest that these agents could also 
possess anti-fibrotic pharmacological activity due to their ability (sb4 and its analogs) to both 
activate and enhance BMP signaling. Therefore, future studies could test the effects of sb4 in 
combination with current therapies used to treat chronic kidney disease. For example, studies have 
been already been conducted to test the effects of anti-TGF-b therapy combined with RAAS 
inhibitors, as well as, BMPs combined with RAAS inhibitors [27, 34]. These studies have shown 
an increased therapeutic benefit that results in further disease reduction than these agents 
administered alone. Hence, future studies to assess the effects of anti-TGF-b therapy in 
combination with sb4, or sb4 in combination with RASS inhibitors in animal models of chronic 
kidney disease are warranted. RAAS inhibitors would be expected to slow the progression of 
disease while sb4 may simultaneously reverse the disease by stimulating BMP signaling to 
regenerate damaged renal cells.  
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As discussed in this dissertation, BMPs play a crucial role in kidney development [10]. 
Therefore, future studies to evaluate the potential capacity of sb4 to induce nephron progenitor cell 
proliferation similar to BMPs in embryonic renal organoid cultures will provide further insight 
into the mechanism of action of sb4. It will also strengthen the rationale of testing sb4 in animal 
models of chronic kidney disease. Specifically, if future studies find that sb4 stimulates the 
proliferation of nephron progenitor cells, such findings could imply that sb4 may also have the 
potential to stimulate the proliferation of damaged tubular epithelial cells of the nephron after 
injury similar to BMPs. Several of the other small-molecules that activate BMP signaling 
identified in this dissertation could also possess similar effects. Further experimentation will be 
required to determine how these BMP signaling agonists effect various cell types of the kidneys.   
Prior to conducting pre-clinical animal studies, pharmacokinetic studies will be necessary. 
In particular, carrying out mouse liver microsomal assays will allow for assessment of the stability 
of sb4 in vivo. These future studies will help identify metabolic liabilities and support SAR studies. 
It should be considered too that even if these BMP signaling agonists are successful in pre-clinical 
animal models of chronic kidney disease limitations exist in utilizing these therapeutic approaches 
clinically. For instance, a potential therapy like sb4 would likely be most effective during the early 
stages of kidney disease. However, most CKD patients are unaware that they have kidney disease 
as it can progress for decades without noticeable symptoms. Therefore, it is critical to develop 
novel small-molecules that encourage the regeneration and repair of damage kidney tissues, as 
well as, identify biomarkers for early kidney disease and patients at risk for disease progression. 
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Future investigations to further develop the identified Pax2 inhibitors 
 
As discussed in Chapters 1 and 4, Pax2 plays a role in the progression of proliferative 
diseases of the kidney such as polycystic kidney disease (PKD) and clear cell renal cell carcinoma 
(ccRCC). Appropriately, Pax2 is a potential therapeutic target in these diseases. The second aim 
of the work described in this dissertation was to identify small-molecules that inhibit Pax2 activity. 
Re-mining screens of over 300 compounds detailed in this dissertation identified 122 more Pax2 
inhibitors which grouped into many clusters. Several Pax2 inhibitors from the top clusters were 
fresh powder tested. An emerging lead series of Pax2 inhibitors were found from the fresh powder 
dose-response experiments. The lead series contains compound EG-H26 which is an inhibitor of 
Pax2 activity first identified and reported by Grimley [35]. Since the original inhibitors from the 
re-mining screen were confirmed by fresh powder, initial SAR analysis for the original 122 CCG 
inhibitors was conducted. Initial SAR analysis was performed on 34 compounds with similar 
structures to EG-H26.  
Future studies will include a more detailed SAR analysis after resynthesizing the 
compound with the best potency and efficacy from the lead series. Synthesis and testing of novel 
analogs similar to the most potent and efficacious compound may also be necessary to aid a more 
in-depth SAR analysis. Determination of the best compound will be assessed by testing in 
secondary assays. These secondary experiments will employ embryonic kidney organoids which 
will be assessed for 1) disturbed ureter tip bud branching morphogenesis and 2) defects in Pax2+ 
cell aggregation at ureter tip buds after Pax2 inhibitor treatment. Assessment of suppressed Pax2 
activity in renal cancer cell lines after treatment with Pax2 inhibitors will also be conducted. 
Isothermal Titration Calorimetry (ITC) assays will too be of great importance. ITC assays will 
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help distinguish which compounds in the emerging lead series bind to Pax2. Data from ITC assays 
may also support in-depth SAR studies and help design improved Pax2 inhibitors.   
Given that these Pax2 inhibitors were identified using HTS methodologies, it is possible 
that they could exert their inhibitory effects in numerous and novel ways. Some possible 
mechanism that may inhibit Pax2 activity include interference with the protein-protein interaction 
between Pax2 and PTIP (adaptor protein linking Pax2 to activating gene epigenetic complexes 
[36-38]). Alternatively, even if the interaction between Pax2 and PTIP remains intact with Pax2 
inhibitor treatment, these Pax2 inhibitors could prevent the ability of PTIP to recruit activating 
epigenetic complexes to Pax2. Future experiments would then include the assessment of the ability 
of the these Pax2 inhibitors to interfere with Pax2 activity not only at the level of DNA binding 
but also at the epigenetic level. For instance, studies can be conducted to determine if the proteins 
in the activating epigenetic complex ChIP to the Pax2 binding DNA element in a Pax2 dependent 
manner. Hence, experiments to determine which of the proteins in the epigenetic complex still 
ChIP to the Pax2 binding DNA element in the presence of these Pax2 inhibitors will provide further 
insight into their mechanisms of inhibition.  
Determining the mechanism of action of the compounds in the emerging lead series of 
Pax2 inhibitors will ultimately help design future compounds that are optimal in potency, 
selectivity, and efficacy. However, prior to testing these Pax2 inhibitors in animal models of PKD 
or ccRCC it will be essential to conduct pharmacokinetic assays to assess for in vivo stability of 
these compounds. If optimized Pax2 inhibitors are successful in pre-clinical studies translation to 
clinical settings could be promising. However, clinical success will depend on many factors. In 
particular, early detection and proper characterization of PKD and ccRCC will be key in reducing 
cystogenesis in PKD and slowing the progression of ccRCC with Pax2 inhibitors.  
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